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ABSTRACT 
 
Vagus nerve stimulation (VNS) is a neuromodulatory approach that involves 
delivering electrical impulses to the vagus nerve to modulate the autonomic nervous 
system. In addition to being FDA-approved for use in epilepsy and depression, a plethora 
of both experimental and clinical studies also supports the potential of VNS to treat 
cardiovascular diseases. While promising, the precise mechanism by which this therapy 
exerts its cardioprotective effects are not well-established.  
The central dogma states that vagus nerves primarily innervate the atria with very 
minimal to no innervation into the ventricles. Based on this concept, parasympathetic 
system activation by VNS should not significantly affect ventricular properties. This is not 
the case, however, as VNS has been extensively shown to exert marked anti-arrhythmic 
effects in the ventricles. Furthermore, this supposition that there is minimal vagal 
innervation into the ventricular myocardium has been challenged by a series of 
immunohistochemical, histological, and western blot experiments. The first aim of my 
dissertation was to investigate the potential for a direct effect of long-term VNS on 
ventricular electrophysiology and test the hypothesis that VNS induces electrical 
remodeling of the ventricles to render the therapy’s reported anti-arrhythmic effects. 
Secondly, I then examined the direct contributions of the M2 muscarinic receptor activated 
potassium channel (M2R-IKACh) in mediating the chronotropic effects of VNS. For this 
second aim, I applied VNS on several transgenic mice that lack the IKACh channel 
constitutively, and selectively in the atria or the ventricles. Thirdly, there still does not exist 
a universally accepted published prospective VNS paradigm, which further highlights the 
vi 
 
complexity of parameter optimization. This work introduced an innovative concept of 
incorporating stochasticity when stimulating the vagus nerve (stochastic VNS, S-VNS) and 
I evaluated the effects of S-VNS on acute heart rate (HR) dynamics in comparison to 
traditional, periodic VNS. Collectively, the work performed in this thesis contribute to the 
mechanistic understanding of VNS therapy, in particular to the fundamental role of the 
parasympathetic nervous system in ventricular electrophysiology, and facilitate the 
optimization and improvement of VNS efficacy.  
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CHAPTER 1 INTRODUCTION 
1.1 Neuromodulation Therapy: An Emerging Field 
Neuromodulation is one of the most rapidly growing fields in medicine today that 
encompasses a wide range of implantable or noninvasive interventional approaches to treat 
neurological and other nervous system disorders. This therapy involves altering the central 
or peripheral nervous systems, either electrically or chemically, to inhibit, excite, and/or 
modify the neural activity to achieve therapeutic outcomes (Krames et al., 2009).   
To date, a plethora of neuromodulation techniques have been utilized to treat 
movement disorders, epilepsy, psychiatric disorders, chronic pain, addiction, and others 
(Krames et al., 2009). Some examples of these therapies include but not limited to deep 
brain stimulation, transcranial direct current stimulation, spinal cord stimulation, and vagus 
nerve stimulation (VNS). For my thesis research, I used VNS and investigated the therapy’s 
effects on the dynamics of the heart using animal models. 
1.2 General Physiology of the Heart 
The heart is a muscle that facilitates blood flow through the vascular system to 
supply nutrients throughout the body and to re-oxygenate blood via pulmonary circulation. 
The heart consists of four chambers as shown in Fig. 1.1. The left and right atria are the 
two chambers that receive blood while the left and right ventricles pump blood out of the 
heart. The left side of the heart is responsible for distributing oxygenated blood throughout 
the body; whereas, the right side receives the deoxygenated blood from the body and pump 
it to the lungs in order for the lungs to get re-oxygenated.  
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.  
1.2.1 The Electrical Conduction System of the Heart 
In order for the heart to function properly, it needs to contract and relax in a 
coordinated fashion. The mechanical contractions of the heart are triggered by electrical 
waves of excitation propagating through the cardiac tissue. In healthy hearts, the electrical 
impulses originate in the heart’s own natural pacemaker, the sinoatrial (SA) node in the 
right atrium. From the SA node, the electrical impulse excites the atria and causes it to 
contract. Then, after a short delay to allow enough time for the ventricles to fill up, the 
electrical wave travels through the atrioventricular (AV) node, which serves as the 
electrical connection between the atria and the ventricles, to the Purkinje fibers via the 
Bundle of His. Finally, the Purkinje fibers will carry the electrical wave to the ventricles 
causing them to contract. A representation of the anatomy of the electrical conduction 
system in the heart is shown in Fig. 1.2. 
The contraction of the heart is a phenomenon that is brought about by a well-timed 
summation of single cardiomyocyte contractions. The contraction of each myocyte is 
triggered by the electrical wave of excitation that originates from the SA node. Each time 
a myocyte is triggered, the properties of transmembrane ion channels (e.g. sodium, 
potassium, calcium…) change and a complex movement of ions in and out of the cell takes 
place, thereby causing a cyclic change in the membrane potential. This sequence of changes 
in the membrane potential is known as the action potential. The action potential of one 
myocyte will act as the stimulus to surrounding cells though gap junctions and diffusion, 
thus, eliciting an action potential in downstream cells in the conduction system. This 
process is repeated until the electrical signal propagates through the entire heart causing 
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the whole heart to contract. Fig. 1.2 also shows the shape of the action potential of the SA 
node and cardiomyocytes, and are represented along with respective resting potentials and 
different phases. 
 
Figure 1.1: Schematic illustration of the heart. From (Texas Heart Institute, 2016) . 
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Figure 1.2: Schematic diagram of the electrical conduction system. Here summarizes the 
electrical conduction in the heart and the cardiac action potentials of SA node cells and 
other myocytes showing the different phases (Monteiro et al., 2017). 
 
1.3 The Cardiac Autonomic Nervous System 
Neurons have a soma, axon (or nerve fibers), and a nerve terminal where neurotransmitters 
are released from vesicles to receptors. Clusters of soma in the central nervous system are 
called nuclei; whereas, those located in the autonomic nervous system are called ganglia. 
The autonomic nervous system is part of the peripheral system that regulates visceral 
functions such as HR, blood pressure, and digestion to ensure the stability of the body’s 
internal environment. It has two main subdivisions: the sympathetic and parasympathetic 
nervous systems. Both of these systems function automatically and subconsciously in an 
involuntary manner (Bush et al., 2016).  
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The sympathetic nervous system is associated with the “fight-or-flight’ response of 
the body in cases of stress or danger. Whereas, the parasympathetic nervous system 
promotes all of the body’s internal responses that are associated with a relaxed state (“rest-
and-digest”). Hence, the sympathetic and parasympathetic branches have traditionally been 
regarded as acting in an antagonistic manner (Gordan et al., 2015; McCorry, 2007). 
Specifically, in terms of the heart, the sympathetic nervous system provides excitatory 
stimulation, resulting in positive inotropic (contractility), dromotropic (conduction), and 
chronotropic (heart rate) effects. In contrast, the parasympathetic nervous system opposes 
the effects of the sympathetic by providing inhibitory effects (McCorry, 2007).  
1.4 The Extrinsic Cardiac Autonomic Nervous System 
The autonomic control of the heart is complex and may be divided into two 
components: extrinsic and intrinsic (Ardell et al., 2015; Armour et al., 1997; Park and Cho, 
2014). I will first discuss about the extrinsic cardiac autonomic nervous system which 
consists of fibers mediating connections between the heart and the nervous system (Park 
and Cho, 2014; Shen and Zipes, 2014). An overview of the cardiac innervation is shown 
in Fig. 1.3. 
Both divisions of the autonomic nervous system require two neurons in order to 
transmit efferent information from the central nervous system to peripheral organ systems: 
preganglionic and postganglionic. As the name suggest, preganglionic fibers refer to those 
that precedes the ganglia, and post-ganglionic fibers are fibers that arise from the ganglia 
itself and come in contact with an effector organ such as the heart. In general, the 
sympathetic preganglionic fibers are short, but the postganglionic fibers are long. 
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Conversely, in the parasympathetic nervous system, the preganglionic fibers are long and 
the postganglionic fibers are short (Gordan et al., 2015; McCorry, 2007). In addition to 
efferent fibers, there are also afferent autonomic fibers that project sensory information 
about the state of the body to the brainstem and higher centers (Gordan et al., 2015). These 
afferent signals arise from the renal nerves of the kidneys, baroreceptors located in blood 
vessels, carotid bodies located on the external carotid arteries, and ganglionated plexi (Linz 
et al., 2014).  
In order to control the function of the heart, both the sympathetic and 
parasympathetic system releases neurotransmitters that interact with receptor sites on 
cardiomyocytes. Regardless of which division, all preganglionic fibers are cholinergic, 
meaning that these fibers use acetylcholine (ACh) as the neurotransmitter. To induce the 
excitatory and inhibitory effects on the heart, the sympathetic system releases 
norepinephrine (NE) while the parasympathetic system releases ACh from their 
postsynaptic neurons, respectively.  
1.4.1 Sympathetic Innervation of the Heart 
Sympathetic innervation of the heart arises from the thoracolumbar segments of the 
spinal cord, specifically from T1 to L2, bilaterally. The pre-ganglionic sympathetic fibers 
originate in the lateral gray matter of the spinal cord and synapse with the post-ganglionic 
sympathetic neurons either in the cervical or the thoracic ganglia of the sympathetic chain 
located along the side of the viscera column (i.e., paravertebral ganglia) (Gordan et al., 
2015). From the sympathetic chain, the post-ganglionic fibers then innervate both the atrial 
and ventricular myocardium (Triposkiadis et al., 2009). 
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As mentioned previously, a majority of the postganglionic fibers of the sympathetic 
system are adrenergic since they release NE which then bind to adrenergic receptors. There 
are two types of adrenergic receptors:  and . In the cardiovascular system, there are 1, 
2, 1, and 2. 1 receptors are the predominant receptor type in number and function 
(McCorry, 2007). Activation of these adrenergic receptors by NE initiates a cascade of 
signaling pathways via the G protein subunit alpha complexes (G), leading to the 
activation of adenyl cyclase and subsequently increased calcium influx (Harvey, 2012; 
Linz et al., 2014).  
1.4.2 Parasympathetic Innervation of the Heart and the Vagus Nerve 
The vagus nerve, or also known as the tenth cranial nerve, is the longest of the 
twelve cranial nerves in the human body. Originating in the medulla oblongata, the vagus 
nerve is composed of roughly 80% afferent and 20% efferent fibers (Howland, 2014; Seki 
et al., 2014; Vonck et al., 2007). The vagus nerve consists of approximately 75% of all 
parasympathetic fibers (McCorry, 2007). The nerve fibers of the vagus can be classified 
into A, B, or C types, and each has activation properties that are distinctly different 
(AgostoniI et al., 1957; Byku and Mann, 2016; Castoro et al., 2011). Type A (diameter, 5 
– 20 µm) and Type B (diameter, 1 – 3 µm) are large, myelinated fibers and have high 
conduction velocities; whereas, Type C (diameter, 0.2 - 2 µm) are the smallest, 
unmyelinated, and have the slowest conduction velocities (Castoro et al., 2011). In general, 
Type A fibers, especially those that are above 12 µm, provide efferent motor control of the 
laryngeal muscles, while Types B and C fibers provide autonomic control of the heart (Yoo 
et al., 2016).  
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In general, the afferent sensory fibers transmit information via the nodose ganglion 
and synapse in the nucleus tractus solitarius (NTS) of the brainstem (Kapa et al., 2016). 
From there, the NTS provides connection to the dorsal motor nucleus (DMN) of the vagus 
and the nucleus ambiguus, where the efferent preganglionic parasympathetic fibers to the 
heart originate (Kapa et al., 2016). These efferent preganglionic fibers do not directly 
innervate the heart but rather synapse within the intrinsic cardiac ganglia that primarily lies 
on the ventral and dorsal fat pads of the heart. From these fat pads, the postganglionic 
efferent parasympathetic fibers then heavily innervate the SA and AV nodes and sparsely 
into the ventricular myocardium (Kapa et al., 2016). This concept of sparse 
parasympathetic innervation in the ventricles, however, has since been challenged (see 
Section 1.8 for more details). 
ACh is the predominant neurotransmitter from the parasympathetic nervous 
system, in both the preganglionic and postganglionic neurons. ACh can bind to two types 
of receptors: nicotinic receptors and muscarinic receptors. Nicotinic receptors produce 
rapid, excitatory responses and are located at the synapses between the preganglionic and 
postganglionic neurons. Muscarinic receptors are located in the postganglionic neurons of 
the heart and compared to nicotinic receptors, the responses are slower in comparison. In 
terms of the parasympathetic control of the heart, the muscarinic M2 receptors are the 
primary mediators (Heller Brown and Laiken, 2012). Activation of the M2 receptors will 
slow pacemaker depolarization and the sinus rate via the pertussis toxin-sensitive Gi/o 
proteins to inhibit adenyl cyclase, reduce cyclic adenosine monophosphate (cAMP), and 
open the IKACh channel (Harvey, 2012; Liang et al., 2014; Wydeven et al., 2014). 
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Figure 1.3: Overview of the cardiac innervation by the autonomic nervous system. 
Figure adapted from (Végh et al., 2016).  
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1.5 The Intrinsic Cardiac Autonomic Nervous System 
Briefly, the intrinsic cardiac nervous system is a complex neural network that is 
comprised of ganglionated cardiac plexuses that is mainly embedded within the epicardial 
fat on the surfaces of the atria (i.e., SA and AV nodes and the pulmonary vein-left atrium) 
and ventricles (i.e., primarily located at the origins of the several major cardiac blood 
vessels) (Linz et al., 2014; Shen and Zipes, 2014). These ganglia contain local circuit 
neurons that can respond and maintain beat-to-beat control of cardiac function. These 
ganglionated plexus can act as integration centers that regulate the interaction between the 
extrinsic and intrinsic cardiac nervous system via modulating the activity of the other 
through efferent and afferent connections. Or the intrinsic cardiac system may act entirely 
independent from the influences of the central or peripheral nervous system components 
(Ardell et al., 2015; Kapa et al., 2016).  
1.6 VNS Therapy 
VNS is a neuromodulatory treatment that stimulates the vagus nerve. The therapy 
consists of an implanted pacemaker-like pulse generator and a nerve stimulation electrode 
that delivers mild electrical impulses to the patient’s vagus nerve. A thin thread-like 
flexible wire, attached to the generator, runs under the skin to the vagus nerve. Fig. 1.4 
describes the VNS system.  
1.6.1 FDA-approved Treatment for Epilepsy and Treatment-Resistant 
Depression 
Since the late 19th century, VNS has been used as a therapy to treat epilepsy (Yuan 
and Silberstein, 2016b). In fact, early animal studies demonstrated that VNS was able to 
alter the activity of the brain, suppress seizures and tremors, and induce an extended period 
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of seizure inhibition post-VNS. With these successes, human trials were then conducted 
and significant seizure reduction in patients diagnosed with intractable epilepsy was 
demonstrated (Ben-Menachem et al.; Penry and Dean, 1990; Uthman et al., 1993). The 
United States Food and Drug Administration (FDA) then approved the use of VNS to treat 
intractable epilepsy in 1997 (O’Reardon et al., 2006). In addition, it was observed that 
epileptic patients who underwent VNS treatment showed mood improvements (Elger et al., 
2000). Hence, Rush et al conducted an open trial using VNS to treat adult outpatients with 
nonpsychotic, treatment-resistant major depressive or bipolar disorders (Rush et al., 2000). 
The results from this study suggest that VNS has antidepressant effects, and the FDA 
approved the use of VNS for treatment-resistant depression in 2005 (O’Reardon et al., 
2006; Rush et al., 2000). In addition to its antidepressant and antiepileptic effects, electrical 
stimulation of the vagus nerve has also been proposed to be able to treat other medical 
diseases such as obesity, headaches, and gastric motility disorders (Akdemir and Benditt, 
2016; Yuan and Silberstein, 2016a).  
Figure 1.4: Illustration of the VNS system. (A) VNS pulse generator implanted with lead 
wrapped around patient’s vagus nerve and (B) handheld programmer and wand to 
communicate with the pulse generator via telemetry to noninvasively program, retrieve 
data, and perform device diagnostics. Figure adapted from (Dicarlo et al., 2013). 
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1.6.2 Potential to Treat Cardiovascular Diseases 
According to the American Heart Association, cardiovascular diseases remains to 
be the leading cause of death in the USA, accounting for nearly 801,000 deaths in the USA 
alone (Benjamin et al., 2017). While pharmacotherapy and mechanical devices have 
improved clinical outcomes, the morbidity and mortality rates of heart failure (HF) still 
remains high (Swedberg et al., 2008). Currently, the only approach to conclusively treat 
HF patients is heart transplantation. This therapy, however, has risks and limitations: its 
invasiveness, cost, and the limited number of donor organs available (Bernstein and 
Srivastava, 2012). As a result, there is a huge need for new approaches and more effective 
cardiovascular therapies.  
The pathophysiology of HF and other cardiovascular diseases such as hypertension 
and myocardial infarction (MI) are often associated with neurohormonal activation of the 
sympathetic nervous system and withdrawal of the parasympathetic system. In the early 
stages of HF, activation of the sympathetic nervous system serves as a compensatory 
physiological response for the heart to induce positive inotropic and chronotropic effects 
to meet the increased physiologic and metabolic demands. However, this excessive 
upregulation of the sympathetic nervous system will eventually contribute to the 
progression and pathogenesis of HF. 
Over the past decades, VNS has been extensively studied as a potential therapy for 
HF. Here, the aim of the therapy is to modulate the parasympathetic activity in order to 
reestablish the cardiac autonomic balance in response to the increased sympathetic tone 
seen in cardiac diseases (De Ferrari et al., 2011; Klein and Ferrari, 2010; Li et al., 2004). 
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The therapeutic effects have been investigated in several animal models, and they suggest 
chronic VNS might have significant positive effects in the failing heart. 
First, preclinical results from Li et al have shown that HF rats treated with VNS 
showed significant improvements in LV hemodynamics and decreased mortality from 50% 
to 14% (Li et al., 2004). Furthermore, it was also demonstrated in a high-rate ventricular 
pacing HF canine model that the animals receiving VNS treatment had significantly lower 
LV end-diastolic and systolic volumes and higher LV ejection fraction (Zhang et al., 
2009b). In addition to its hemodynamic effects, VNS has also been shown to be able to 
attenuate LV remodeling associated with HF (Liu et al., 1997). Furthermore, VNS has also 
been shown to exhibit anti-arrhythmic (De Ferrari and Schwartz, 2011; Schwartz and De 
Ferrari, 2009; Wu and Lu, 2011) and anti-inflammatory (Borovikova et al., 2000; Calvillo 
et al., 2011; Mihaylova et al., 2012; Yamakawa et al., 2013) effects. 
Based on the encouraging results of the preclinical studies, a number of clinical 
studies have been conducted (Gold et al., 2015). One such clinical study was the 
ANTHEM-HF and its subsequent extension study (ENCORE) which have yielded 
favorable and encouraging results as VNS patients showed significant improvements in 
LV structure and function, decreased HF symptom expression and decreased T-wave 
alternans, which is a measure of electrical instability (Gold et al., 2015; Nearing et al., 
2016; Premchand et al., 2014, 2015).  
Furthermore, VNS is also a promising alternative approach to current treatments of 
cardiovascular diseases (e.g., oral medication and ablative therapies) because as mentioned 
previously, the vagus nerve directly innervates the heart allowing VNS to potentially 
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provide a stronger and quicker response. Furthermore, it is notable that, relative to 
adjusting medication levels, the effects of VNS can be much more quickly adjusted by 
changing stimulation parameters. In other words, VNS provides the advantage of higher 
spatiotemporal precision and reversibility that is absent from oral medications and other 
invasive approaches (Johnson et al., 2013). 
1.7 Mechanisms Underlying the Beneficial Effects of VNS 
Remains to be Further Elucidated 
In spite of the above-mentioned studies demonstrating the therapeutic potential of 
VNS, the precise mechanisms of this therapy are not well-established. A variety of 
mechanisms by which VNS exerts its cardioprotective effects have been proposed and are 
supported by animal studies, including:  
• HR reduction leading to improvements in LV function by reducing cardiac 
workload (Klein and Ferrari, 2010; Sabbah, 2011); 
• Inhibition of proinflammatory cytokine release, through activation of the α7 
nicotinic ACh receptor, and thereby prevent cardiac tissue injury and cell 
death (Borovikova et al., 2000; Calvillo et al., 2011; Mihaylova et al., 2012; 
Yamakawa et al., 2013); 
• Normalization of nitric oxide signaling (NOS) pathway, specifically 
improve expression of endothelial (eNOS) and normalize the expressions 
of induced (iNOS) and neuronal (nNOS) in the HF-induced myocardium 
(Kalla et al., 2016; Sabbah, 2011); and 
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• Preservation of connexin-43 (Cx-43) which are protein molecules that form 
gap junctions. Intercellular electrical coupling mainly occurs through gap 
junctions and during cardiac diseases (Gutstein et al., 2001; Jiang et al., 
2008; Lerner et al., 2000; Papp et al., 2007), it has been shown that the 
amount and distribution of Cx-43 are significantly altered (Ando et al., 
2005; Wu and Lu, 2011). 
While these proposed mechanisms may be able to partially explain the beneficial 
effects of VNS, it is yet to be explained how stimulating the vagus nerve can induce anti-
arrhythmic actions in the ventricles. Hence, one of the main objectives of my thesis work 
was to further improve our understanding of how the parasympathetic branch influences 
ventricular physiology. This is especially crucial since now there are emerging evidences 
suggesting significant innervation of the vagus into the ventricles than what was initially 
perceived. 
 
1.8 ‘Realities’ of the Cardiac Parasympathetic Innervation into 
the Heart 
The myocardium is innervated by both sympathetic and parasympathetic nerves. 
The dogma of physiology teaching states that there are significant innervation of the 
sympathetic postganglionic nerves into the atria, SA and AV nodes, and the ventricles; 
whereas, the parasympathetic postganglionic nerves are limited to only the atria, and if any, 
very sparse innervations into the ventricles. As a result, it was initially postulated that there 
should minimal to no direct influence of the parasympathetic branch on ventricular 
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performance (Coote, 2013; Jungen et al., 2017; Végh et al., 2016). This supposition, 
however, has recently been challenged by several studies. 
1.8.1 Histochemical Evidences 
In the early 1950s and 1960s, the laboratory of Koelle and Kanovasky & Roots 
developed a thiocholine staining method to identify acetylcholinesterase (AChE), which is 
the enzyme responsible for hydrolyzing ACh (Karnovsky and Roots, 1964; Koelle, 1955). 
As a result of this staining method, several researchers have shown that there are indeed 
parasympathetic innervation into the ventricles of several species such as rats, pigs, 
humans, canine, and cats (Coote, 2013; Jacobowitz et al., 1967; Kent et al., 1974; Taggart 
et al., 2011; Ulphani et al., 2010; Zang et al., 2005).  
In addition to staining for AChE, parasympathetic distribution into ventricles was 
also confirmed using immunohistochemical method for choline acetyltransferase (CHAT) 
(Coote, 2013; Pauza et al., 2013; Yasuhara et al., 2007). CHAT is an enzyme that catalyzes 
the transfer of an acetyl group from acetyl-CoA to choline, synthesizing ACh (Oda, 1999). 
1.8.2 Microdialysis and Molecular (Muscarinic) Evidences  
Evidence of postganglionic parasympathetic innervation in the ventricular 
myocardium may also be assessed by measuring ACh concentrations released during 
cervical VNS. Using microdialysis technique, several researchers have shown in both mice 
and cats that electrical stimulation of the vagus nerve increased ACh from postganglionic 
vagal nerve terminals in the ventricle. Whereas, transection or pharmacological blockade 
of the vagal nerve postganglionic terminal prevented the effect of VNS on ACh release 
(Akiyama and Yamazaki, 2001; Kawada et al., 2001; Zhan et al., 2013). 
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Muscarinic receptors are one of the primary binding sites for ACh, and they are 
expressed in the postganglionic terminals of the heart. The muscarinic M2 subtype 
receptors are the primary mediators in parasympathetic regulation of the heart (Heller 
Brown and Laiken, 2012). Using RT-PCR and western blotting techniques, expressions of 
the M2 and other muscarinic receptor subtypes have been identified in the ventricles in 
various species, although it is significantly lower than what is expressed in the atria (Krejcí 
and Tucek, 2002; Wang et al., 2001; Zang et al., 2005).  
 
1.9 Research Objectives and Organization of Thesis 
As mentioned thus far, in spite of several studies demonstrating the therapeutic 
potential of VNS to treat cardiac diseases, the mechanism of action of VNS remains 
unclear. One of many reasons for this is due to the myriad of experimental factors and 
stimulation parameters used in studies; thus, making probing the physiological mechanism 
of action of VNS extremely challenging to understand. This is because VNS can have 
different effects depending on the parameters and level of stimulation used. Furthermore, 
it was widely believed that the parasympathetic system had minimal to no influence on 
ventricular physiology since the postganglionic vagus nerve only sparsely innervates the 
ventricles, However, an abundance of histological and experimental studies have since 
argued this supposition.  
Hence, the focus of my research is as follows: First, I investigated the effects of 
VNS on the electrophysiological properties of the ventricles in order to gain a better 
understanding and determine whether ventricles may play a role in the therapeutic 
mechanisms of VNS. Second, I used novel genetic mouse lines to further investigate the 
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role of M2 receptors in mediating the chronotropic effects of VNS. Third, I developed and 
investigated a novel stimulation paradigm to electrically stimulate the vagus nerve in order 
to further optimize and improve VNS efficacy. The overall aim of this dissertation is to 
improve our knowledge of VNS and to elucidate the mechanism of action in order to 
further optimize and improve VNS efficacy. The thesis is divided into the following 
chapters: 
Chapter 2 describes the study used to demonstrate the therapeutic effects of VNS 
in a chronic MI rat model. In this study, I looked into the electrophysiological changes 
induced by long-term VNS in the atria of MI hearts. Through this study, I investigated and 
gained a better understanding of how both chronic MI and VNS affected the atria, 
especially since there is significant vagal fiber innervation into the atrium and it remains 
unclear how chronic ventricular MI affects atrial properties. Details of the experimental 
investigations performed and the results are also provided.  
Due to the emergence of evidences supporting significant parasympathetic 
innervation and possibly more influence on ventricular physiology than what was initially 
perceived, Chapter 3 discusses the research study performed to investigate the effects of 
stimulating the vagus nerve of healthy rats when the autonomic nervous system is in 
balance. It details the use of optical imaging techniques to compare the ventricular 
electrophysiological properties between VNS-treated and non-treated hearts. Furthermore, 
testing in normal, healthy controls is essential to understanding the mechanism of VNS and 
evaluate any potential negative effects the therapy may have without the interferences of 
other confounding factors.  
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After showing that VNS modifies both atrial and ventricular electrophysiological 
properties in Chapters 2 and 3, respectively, in the whole-heart level, Chapter 4 
investigates from a molecular standpoint. Specifically, Chapter 4 details the application 
of VNS on novel transgenic mouse lines that lack the M2R-IKACh signaling pathway 
constitutively, and selectively in the atria/SA node or ventricles. The goal of the study was 
to distinguish the specific role of cardiac IKACh in mediating the chronotropic effects of 
acute VNS on the heart. To our knowledge, this study is the first to probe the direct link 
between VNS and M2R-IKACh channel in a tissue-specific area of the heart (i.e. atria and the 
ventricles) in-vivo. 
There still does not exist a universally accepted published prospective VNS 
paradigm, which further highlights the importance and complexity of parameter 
optimization. To further optimize and improve VNS efficacy, Chapter 5 describes an 
investigative study performed to evaluate the effects of incorporating stochasticity when 
stimulating the vagus nerve (stochastic VNS) on acute heart rate (HR) dynamics. The effect 
of stochastic VNS was evaluated in rats by comparing the acute HR and HR variability 
(HRV) responses to standard, periodic VNS.  
Chapter 6 summarizes the work completed as part of this dissertation by 
highlighting the major findings and discussing the possible future directions for this 
research. 
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CHAPTER 2 EFFECTS OF VNS 
ON ATRIAL 
ELECTROPHYSIOLOGICAL 
PROPERTIES 
 
(Published) 
X. Xie*, S.W. Lee*, C. Johnson, J. Ippolito, B.H. KenKnight, and E.G. Tolkacheva, 
“Intermittent Vagal Nerve Stimulation Alters the Electrophysiological Properties of 
Atrium in the Myocardial Infarction Rat Model,” Conf Proc IEEE Eng Med Biol Soc. 
2014; 2014: pages 1575-1578. [*Authors contributed equally to the study] 
 
2.1 Chapter Synopsis 
Intermittent vagal nerve stimulation (VNS) has emerged as a potential therapy to 
treat cardiovascular diseases by delivering electrical stimulation to the vagus nerves. The 
purpose of this study was to investigate the electrophysiological changes in the atrium 
resulting from long-term intermittent VNS therapy in the chronic myocardial infarction 
(MI) rat model. MI was induced via left anterior descending coronary artery (LAD) ligation 
in male Sprague-Dawley rats, randomized into two groups: MI (implanted with 
nonfunctional VNS stimulators) and MI-VNS (implanted with functional VNS stimulators 
and received chronic intermittent VNS treatment) groups. Further, a sham group was used 
as control in which MI was not performed and received nonfunctional VNS stimulators. At 
12 weeks, optical mapping of right atrium (RA) of sinus rhythm was performed. Our results 
demonstrated that chronic MI changed the electrical properties of the atrium action 
potentials and resulted in reduced action potential duration at 50% (APD50) and 80% 
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(APD80) repolarization. Chronic right cervical VNS restored the APD back to healthy heart 
APD values. Additionally, APD heterogeneity index increased as a result of the chronic 
MI. Chronic VNS was not found to alter this increase. By calculating PR intervals from 
weekly ECG recordings of anaesthetized rats, we demonstrated that chronic MI and 
intermittent VNS did not affect the AV conduction time from the atria to the ventricles. 
From our study, we conclude the MI decreased the APD and increased APD spatial 
dispersion. VNS increased the APD back to healthy normal values but did change the APD 
spatial dispersion and the electrical conduction in the RA. 
2.2 Introduction 
Myocardial infarction (MI) is the most common cause of heart failure (HF) (Coronel 
et al., 2013; Klocke et al., 2007). Current therapies designed to treat MI patients include 
conventional pharmacological and mechanical device-based interventions. While these 
approaches have improved the prognosis of patients with MI, the mortality rate still remains 
high (Swedberg et al., 2008).  
As mentioned previously, VNS is an adjunctive procedure involving the stimulation 
of the vagus nerve with electrical impulses and is currently used clinically to treat intractable 
epilepsy and treatment-resistant depression (Ghanem and Early, 2006; Groves and Brown, 
2005). Recently, modulation of nerve activity through cardiac VNS has emerged as a 
potential therapy for cardiovascular diseases (De Ferrari et al., 2011). It has been shown that 
chronic VNS can inhibit sudden cardiac death (Vanoli et al., 1991) and markedly suppress 
arrhythmias (Li et al., 2004) in MI animal models. Peripheral cardiac nerve stimulation can 
also modify atrial and ventricular contractile functions (Brack et al., 2011; Kunze, 1972). It 
22 
 
has been reported that chronic VNS may improve left ventricular function and the quality 
of life in chronic HF patients with severe systolic dysfunction (De Ferrari et al., 2011). 
It is well known that parasympathetic vagal nerves extensively innervate the atria. 
The vagus nerve (parasympathetic) system communicates with the heart through the 
intracardiac ganglia, which are divided into the sinoatrial (SA) and atrioventricular (AV) 
nodes (Sampaio et al., 2003). It is thought that VNS might have a significant effect on atrial 
electrophysiological properties due to dense vagal innervations. However, the effects of 
chronic VNS on the atrium remain unclear. Additionally, there are controversial findings 
on whether VNS is linked to atrial fibrillation (AF). Specifically, VNS has been shown to 
shorten the duration of action potential (APD) in atrial myocytes and reduce the atrial 
absolute refractory period, facilitating the induction of AF by a single atrial ectopic beat and 
the presence of multiple reentrant circuits coexisting in the atrial myocardium (Chen and 
Tan, 2007; Zhang and Mazgalev, 2011). Furthermore, animal studies involving vagal 
denervation have suggested that VNS may be proarrhythmic (Lemola et al., 2008; Schauerte 
et al., 2000). Nonetheless, there are also studies that have shown that VNS can inhibit 
spontaneous activities of isolated cardiac myocytes from rabbit pulmonary veins (Chen et 
al., 2002a) and canine superior vena cava (Chen et al., 2002b). In addition, it has been shown 
that the use of phenylephrine to enhance the vagal tone suppresses focal AF originating in 
the pulmonary veins in patients (Tai et al., 2000; Zhang and Mazgalev, 2011). Low-level 
VNS has also been implemented in ambulatory dogs to reduce atrial tachy-arrhythmias 
(Shen et al., 2011). Therefore, further investigations are required to determine the exact role 
of VNS on the electrophysiological properties of atria.  
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The objective of this study was to use high resolution optical mapping techniques to 
evaluate the changes in atrial electrophysiology due to chronic intermittent VNS in a chronic 
MI rat model. We aimed to identify whether these changes might potentially promote or 
inhibit the creation of substrates for atrial arrhythmias. To our knowledge, this is the first 
study to characterize the electrophysiological changes in the atria in MI rat hearts after 
treatment with long-term VNS.  
2.3 Materials and Methods 
2.3.1 MI Rat Model 
All experiments conformed to the Guide for the Care and Use of Laboratory 
Animals (NIH publication No. 85-23, revised 1996) and the University of Minnesota 
guidelines regulating the care and use of animals.  
Male Sprague-Dawley rats (n=6, 250-300g, Charles River Laboratories, 
Wilmington, MA) were randomized into three groups: Sham (n=2), MI (n=2), and MI-VNS 
(n=2). Sham rats underwent open chest and cervical sham surgeries only, while MI was 
induced in both MI and MI-VNS rat hearts. The MI was created through permanent ligation 
of the left anterior descending coronary artery (LAD) in the MI and MI-VNS groups. Rats 
were anesthetized with Isoflurane (3%) during the open chest MI surgeries. Rats were 
intubated with a ventilator (Model 683, Harvard Apparatus) and body temperature was 
maintained at 37°C throughout the surgeries. LAD surgery was performed by ligation of the 
proximal LAD artery with 6-0 silk sutures. Full LAD occlusion was visually confirmed 
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when the myocardium of the left ventricle changed color to a pale blue, reflecting the lack 
of oxygenated blood flow into the region. 
Figure 2.1: Surgical Implantation of VNS in Rats. A) VNS lead placement around the 
cervical vagus nerve and carotid artery bundle. B) Placement of the helical bipolar leads. 
C) Cyberonics 105 Vagal Nerve Stimulator.  
 
2.3.2 VNS Stimulator Implantation 
Immediately after MI surgery, VNS stimulators (Fig. 2.1(c), Cyberonics Model 
103, Houston TX) were implanted subcutaneously on the lower back of the rats. Active 
and non-functional VNS stimulators were implanted in MI-VNS and MI rats, respectively. 
The bipolar cuff electrodes were coiled around the bundle of right cervical vagus nerve and 
carotid artery as shown in Fig. 2.1(b). Intermittent VNS was given to the MI-VNS rats for 
12 weeks. Parameters of VNS stimulation were defined as in previous literature (Li et al., 
2004): stimulation frequency of 20 Hz; pulse width of 500 microseconds; and stimulation 
current of 1 mA; duty cycle of roughly 12% (7 second ON every 1 minute).  
2.3.3 ECG Recordings 
ECG recording was performed as described previously (Ippolito et al., 2014). 
Briefly, ECG recordings was performed in all rats weekly for approximately 20 minutes 
per animal using the iWorx IX-ECG-12 recording system, while rats were lightly 
anesthetized with 2% Isoflurane. Custom-made program in Matlab was written to calculate 
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PR intervals and heart rate (HR) from anaesthetized rats’ ECG data. For each week and for 
each rat, mean PR intervals were calculated over 20 minutes of ECG recording. HR was 
derived from the first 2 minutes of the ECG during which the effects of anesthesia were 
minimal. 
2.3.4 High-Resolution Optical Mapping 
At week 12, rat hearts were extracted. The aorta was quickly cannulated and 
perfused in a retrograde manner using Langendorff-perfusion system with warm (37±1ºC) 
oxygenated Tyrode’s solution.  A dose of 0.01 ml of the fluorescent voltage-sensitive dye 
di-4-ANEPPS (10 µmol/L) was administered to the right atrium (RA) directly. Two diode 
continuous lasers (532 nm, SDL-532-1000 T, Shanghai Dream Lasers Tech., Shanghai, 
China) were used for excitation, and the fluorescence signal was recorded from the RA 
surface by fast (1000 frames per second) 14-bit resolution, 80x80 pixels resolution camera 
(Little Joe, RedShirt Imaging, SciMeasure). The field of view was approximately 6 x 6 mm 
(Fig. 2.2(a)). After stabilization (~30 minutes), optical mapping movies of the whole RA 
were acquired during sinus rhythm.  
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Figure 2.2: Measurements of Atrial APD. A) Optical mapping field of view (indicated by 
dashed lines) of RA. B) A typical action potential trace from pixel marked as “*” of the 
RA demonstrating APD50 and APD80. C) Corresponding 2D APD80 maps to A). D) Mean 
values for APD50 (open bars) and APD80 (filled bars). ψ represents statistical difference 
between APD50 and # represents statistical difference between APD80 (p < 0.05). 
 
2.3.5 Data Analysis 
We analyzed 12 sinus rhythm responses from each rat, for all three groups. Sinus 
rhythm APD was measured at both 50% (APD50) and 80% (APD80) repolarization (Fig. 
2.2(b)), and two-dimensional (2D) APD maps (Fig. 2.2(c)) were constructed to reveal the 
spatial distribution of APDs on the RA surfaces of the heart. The APD heterogeneity, μ, was 
calculated as described previously (Mironov et al., 2008):  
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    µ = 
(APD95%−APD5%)
APD50%
            (1) 
where APD95% and APD5% represent the 95th and 5th percentiles of the APD distribution, 
respectively, and APD50% is the median APD distribution.  
Mean APD and μ were calculated as the following. For each rat, we first calculated 
mean APD and μ from a single sinus rhythm across the entire RA. Then, we performed 
averaging of these mean APD and μ values for all 12 sinus rhythm responses. Data are 
presented as means ± standard error of the mean. Statistical comparisons among the 3 groups 
were performed using an ANOVA statistical test. P < 0.05 was considered to be statistically 
significant. 
2.4 Results 
2.4.1 Effect of VNS on APD and Spatial Heterogeneity 
Fig. 2.2(d) shows mean values for APD50 (open bars) and APD80 (filled bars) of 
Sham (blue), MI (red), and MI-VNS (green) rats during sinus rhythm. Note that MI 
significantly reduced both APD50 and APD80 (p<0.05) of RA. However, this reduction of 
APD at both levels of repolarization was restored upon chronic intermittent VNS 
stimulation back to Sham (healthy) level.  
Fig. 2.3(a) shows representative sinus rhythm traces as well as examples of 2D 
APD80 maps for Sham, MI and MI-VNS rats. Note the enhanced spatial dispersion of APD 
during sinus rhythm for both MI and MI-VNS rats. We quantified these data by calculating 
mean μ values separately for both APD50 (open bars) and APD80 (filled bars). Fig. 2.3(b,c) 
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indicate that MI significantly increased μ in RA (p<0.05), but was not reduced with chronic 
intermittent VNS.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Measurements of Atrial µ. A) Typical samples of 2D APD maps and 
representative sinus rhythm action potential traces (from pixel marked as “*”) from all 
three groups. Mean spatial heterogeneity index μ afor B) APD50 (open bars) and C) APD80 
(filled bars) are shown for Sham, MI and MIa-VNS groups.  ψ  represents statistical 
difference between APD50 and # represents statistical difference between APD80, p<0.05. 
 
2.4.2 Effect of VNS on PR Interval and HR 
To investigate whether VNS affects the electrical conduction time from atria to 
ventricles, we calculated PR intervals from weekly ECG recordings of anaesthetized rats. 
Average data in Fig. 2.4(a) illustrates the absence of any differences in PR intervals of 
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Sham (blue), MI (red) and MI-VNS (green) ECG recording over the duration of study. In 
addition, as seen in Fig. 2.4(b), our chronic VNS treatment did not induce any significant 
changes in HR of the anaesthetized rats. 
 
Figure 2.4: Effect of VNS on PR Interval and HR. A) Mean PR interval over 8 weeks of 
study for Sham (blue), MI (red) and MI-VNS (green) hearts. B) Mean weekly HR over 8 
weeks of study for Sham (blue), MI (red), and MI-VNS (green).   
 
2.5 Conclusions and Discussion 
In this study, we investigated the long-term effects of both MI and intermittent VNS 
on the electrophysiological properties of the atrium in a MI rat model. The main findings of 
our study are as follows: 1) chronic MI decreased APD and the VNS restored the APD 
values during sinus rhythm in rat heart RA. On the other hand, 2) VNS had no effect on 
APD heterogeneity that was increased due to chronic MI. Finally, 3) neither chronic MI nor 
intermittent VNS affected the AV conduction system in the heart.    
There are only few studies on the effects of chronic MI on atrial electrophysiology. 
Previous studies showed inconsistent changes in atrial action potential morphology in 
cardiovascular diseases: APD was increased (Yeh et al., 2008), shortened (Sridhar et al., 
2009), or unchanged (Li et al., 2000). MI-induced HF is often associated with AF (Miyauchi 
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et al., 2003) and our study showed that MI decreases both atrial APD50 and APD80 during 
sinus rhythm. The shortening of the atrial APD could potentially provide substrates for atrial 
arrhythmias since reduction in APD can shorten the wavelength of re-entry (the product of 
both APD and conduction velocity) and increase the number of wavelets during AF (Nattel, 
2002; Zhang and Mazgalev, 2011). On the other hand, chronic VNS increased both the 
APD50 and APD80 values and restored them back to the healthy animal values, which can 
be a potentially anti-arrhythmic effect.  
Our results also indicate that MI increased the spatial APD heterogeneity in the RA. 
However, VNS did not reduce the heterogeneity of the MI hearts towards healthy values. 
This result may explain the reported conflicting results regarding the anti-arrhythmic effects 
in the whole heart induced by the VNS. The increased spatial heterogeneity of APD is 
known to be one of the contributing factors to arrhythmogenesis (Mironov et al., 2008). This 
indicates that the reported anti-arrhythmic effects of VNS in the whole heart level are less 
likely related with the APD spatial heterogeneity in the RA. 
The PR interval is one of the many important parameters used to identify 
cardiovascular diseases. It can be used as an indication of unfavorable alteration in the 
electrical system of the heart. An abnormal PR interval is often associated with SA nodal 
and or AV nodal blocks. Our PR interval results showed that both MI and VNS did not 
affect the PR intervals among the three groups of rats. This could indicate that there were 
no SA nodal and/or AV nodal disturbances. 
The potential benefits of chronic VNS are now being evaluated in human subjects 
diagnosed with chronic, symptomatic HF (Dicarlo et al., 2013). Previously, data from a 
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small pilot study suggested that VNS alters the natural history of HF (De Ferrari et al., 
2011). Large, multi-center, controlled clinical studies are underway and should provide 
additional insights regarding the safety and efficacy of this new therapy for treatment of 
chronic HF.  
A limitation of this study was the limited sample size. Another limitation was the 
use of general anesthesia to perform ECG recordings from the rats. While it is known that 
anesthesia changes the HR (RR interval) of animals in comparison to conscious animal ECG 
recordings, we believe that changes to the PR interval are minimal.   
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CHAPTER 3 EFFECTS OF VNS 
ON VENTRICULAR 
ELECTROPHYSIOLOGICAL 
PROPERTIES 
 
(Published) 
S.W. Lee, Q. Li, I. Libbus, X. Xie, B.H. KenKnight, M.G. Garry, and E.G. Tolkacheva, 
“Chronic cyclic vagus nerve stimulation has beneficial electrophysiological effects on 
healthy hearts in the absence of autonomic imbalance.” Physiol Rep. 2016 May;4(9). pii: 
e12786. doi: 10.14814/phy2.12786) 
 
3.1 Chapter Synopsis 
Cardiovascular disease degrades regulatory function of the autonomic nervous 
system. Cyclic vagus nerve stimulation (VNS) is an already FDA-approved therapy for 
drug-resistant epilepsy and depression and has been shown to normalize autonomic 
function and improve objective measures of heart function and subjective measures of heart 
failure symptoms. However, it remains unclear whether VNS may induce negative effects 
in patients with potentially healthy hearts where VNS can be used for epileptic patients. 
Hence, this study aims to investigate the effects of VNS on the hearts of healthy rats with 
normal autonomic balance. Sprague-Dawley rats were implanted with stimulators and 
randomized to either Sham or VNS groups. Rats in VNS group received 10 weeks of 
chronic intermittent VNS via stimulation of the right cervical vagus nerve. 
Echocardiography was performed at Baseline (prior to VNS), Week 2, and Week 9. After 
10 weeks, high-resolution optical mapping was performed in ex vivo perfused hearts to 
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evaluate the electrophysiological remodeling that occurs in the heart as a result of the VNS 
therapy. Chronic VNS modified the electrophysiological properties of healthy rat hearts by 
reducing the action potential duration at 50% (APD50) and 80% (APD80) repolarization. 
Chronic VNS also affected the restitution properties of the heart at the APD50 level and 
increased myocardial conduction velocity (CV). VNS did not induce any significant 
changes to ventricular ejection fraction (EF) and spatial dispersion of APD, thus indicating 
that VNS did not negatively affect cardiac function. VNS also reduced the susceptibility to 
ventricular arrhythmias (ventricular fibrillation [VF] and ventricular tachycardia [VT]) 
during programmed electrical stimulation. Chronic application of cyclic VNS induces 
changes to the electrophysiological properties of healthy rat hearts. The observed decrease 
in APD and increase in CV suggest that the beneficial effects of VNS do not require the 
presence of existing autonomic imbalance. 
3.2 Introduction 
Vagus nerve stimulation (VNS) is an approved clinical therapy for drug-refractory 
epilepsy and depression, and more than 130,000 VNS therapy systems have been implanted 
since 1995 (Shuchman, 2007). In the past decade, several pre-clinical and clinical studies 
have demonstrated the beneficial effects of VNS on cardiovascular diseases via 
parasympathetic nervous system activity modulation (Beaumont et al., 2015; De Ferrari 
and Schwartz, 2011; Sabbah, 2011).  
The autonomic nervous system consists of two distinct branches: the 
parasympathetic and sympathetic nervous systems. The balance between the two systems 
plays a significant role in regulating cardiovascular functions and specifically, the 
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coordination of the electro-mechanical function of the heart, leading to optimized cardiac 
output under a variety of environmental and metabolic stressors. Heart diseases such as 
chronic heart failure (HF) and hypertension (HTN) are associated with autonomic 
dysregulation characterized by a sustained increase of sympathetic drive and withdrawal 
of parasympathetic activity (Bibevski and Dunlap, 2011; Schwartz and De Ferrari, 2011). 
VNS has emerged as a promising therapy to treat cardiovascular diseases by its proposed 
mechanism to correct this autonomic imbalance (Annoni et al., 2015; Beaumont et al., 
2015; De Ferrari and Schwartz, 2011; Li et al., 2004; Premchand et al., 2015; Schwartz 
and De Ferrari, 2009; Xie et al., 2014).  
Nonetheless, despite the extensive research and advances that have been made in 
recent years to support the concept of electrical VNS as a therapeutic approach, very little 
is known about the effects of chronic VNS on healthy hearts. While it has always been 
known that parasympathetic vagal nerve fibers densely innervate the atria and the sinoatrial 
(SA) and atrioventricular (AV) nodes, it was initially believed by many that vagal fibers 
only sparsely innervate the ventricles (Coote, 2013). However, other studies have 
challenged this supposition and suggest that the vagal fibers in fact play a greater role in 
ventricular function than initially believed (Armour et al., 1997; Coote, 2013; Randall et 
al., 2003; Ulphani et al., 2010).  
As a result of this finding, it is important to gain a better understanding and fully 
characterize how stimulating the vagus nerve may affect the normal heart when the 
autonomic nervous system is in balance. In addition, as applies to any novel therapy, testing 
in normal, healthy controls is essential to understanding the mechanisms of action of VNS. 
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Most importantly, it makes it feasible to evaluate any potential negative effects the therapy 
may have without the interferences of other confounding factors. Moreover, VNS is FDA-
approved to treat epileptic patients; however, the electrophysiological side effects of VNS 
on their potentially healthy hearts are not well characterized. Hence, the main objective of 
this novel study is to investigate the effects of chronic, intermittent VNS on the 
electrophysiological properties of healthy rat hearts.  
3.3 Materials and Methods 
3.3.1 Animal Preparation 
All animal experiments were approved by the University of Minnesota Animal Care 
and Use Committee and were conducted in accordance with both the Institutional and 
National Institute of Health Guidelines for the Care and Use of Laboratory Animals. 
Male Sprague-Dawley rats (n=9, 250-300 grams, Charles River Laboratories, 
Wilmington, MA) were randomized into two groups: Sham (n=6) and VNS (n=3). Sham 
group animals were implanted with non-functional vagus nerve stimulators, and VNS 
group animals were implanted with functional vagus nerve stimulators (Demipulse Model 
103, Cyberonics Inc., Houston, TX, USA). All animals were maintained and monitored for 
a total of 10 weeks. Rats were placed in a quiet, temperature- and humidity-controlled room 
with a 12:12 hour light-dark cycle. Food and water were available ad libitum.  
3.3.2 VNS Stimulator Implantation 
The VNS pulse generator (Demipulse Model 103, Cyberonics, Inc., Houston, USA) 
was implanted subcutaneously on the lower back of the rats as described previously 
(Annoni et al., 2015; Xie et al., 2014). During the surgery, rats were anaesthetized with 
Isoflurane (5% for induction; 2% or 3.5% for maintenance) in oxygen (2 L/min for 
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induction, 1 L/min for maintenance). The rats’ body temperature was maintained at 37°C 
on a temperature-controlled surgical table. Briefly, the back and the neck of the rat were 
shaved, and the right cervical vagus nerve and common carotid artery bundle were isolated 
from the surrounding tissue through a small incision on the neck. The custom 1.5 mm 
diameter helical lead bipolar cuff electrodes were placed around the carotid artery bundle 
containing the vagus nerve. The therapy group received continuous cyclic low-level VNS 
for 10 weeks. Low-level VNS parameters were set as follows: stimulation frequency of 20 
Hz, pulse width of 500 µsec, and stimulation current of 1.0 mA. The pulse generator was 
programmed to deliver continuously cyclic VNS: 7 seconds ON and 66 seconds OFF. The 
effectiveness of VNS and its effect on acute and chronic changes in heart rate have been 
evaluated in previous studies (Annoni et al., 2015; Xie et al., 2014). 
3.3.3 Echocardiography 
Echocardiography was performed in VNS (n=3) and Sham (n=2) rats prior to VNS 
implantation surgery (Baseline), two weeks after surgery (Week 2), and one week prior to 
sacrifice (Week 9). Anesthesia was induced with 2% isoflurane gas in 100% oxygen, and 
transthoracic echocardiography (VisualSonics, VEVO-770 with 700-Series RMV 
Scanhead Probe, Toronto, Canada) was performed. Echocardiographic M-mode images of 
the left ventricle (LV) were obtained using a parasternal short-axis view at the middle of 
papillary muscle level. Left ventricular end diastolic (LVEDV) and systolic (LVESV) 
volumes were measured and used to calculate the percentage of LV ejection fraction (EF), 
an index of LV function, for each animal using the following equation: EF = ((LVEDV-
LVESV) / LVEDV) x 100%. 
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3.3.4 High-Resolution Optical Mapping 
At the end of 10 weeks, VNS (n=3) and Sham (n=4) rats were euthanized and hearts 
quickly extracted through a thoracotomy. Immediately upon removal, the hearts were 
immersed in cold cardioplegic solution (in mM: glucose 280, KCl 13.44, NaHCO3 12.6, 
and mannitol 34). The aorta was then quickly cannulated and perfused (retrograde) with 
warm (37±1°C) oxygenated Tyrode’s solution (in mM: NaCl 130, CaCl2 1.8, KCl 4, MgCl2 
1.0, NaH2PO4 1.2, NaHCO3 24, glucose 5.5, and pH 7.4). The hearts were immersed in a 
chamber and superfused with the same Tyrode’s solution.  
After 30 minutes of stabilization, voltage-sensitive dye (di-4-ANEPPS, 5µg/mL; 
Molecular Probes, USA) was added to the perfusate. Two 532 nm diode continuous green 
lasers (SDL-532-1000 T, Shanghai Dream Lasers Tech, Shanghai, China) were used to 
illuminate both the right ventricles (RV) and LV surfaces of the heart. Fluorescence signals 
from more than 80% of total ventricular surface were captured with two 12-bit charge-
coupled device (CCD) cameras (DALSA, Waterloo, Canada), that ran synchronously at 
600 frames per second with 64 x 64 pixel resolutions. Blebbistatin (10 - 15 µM) was added 
to the Tyrode’s solution to stop heart contractions and reduce motion artifacts (Smith et al., 
2012). 
Hearts were paced periodically. An external stimuli (5 ms duration, twice the 
activation threshold) were applied to the base of the RV at progressively decreasing basic 
cycle length (BCL) from 200 ms in steps of 20 ms until BCL reached 80 ms; or until 
ventricular tachycardia (VT) or fibrillation (VF) was initiated (Annoni et al., 2015). If and 
only when VF/VT was not induced during periodic pacing, a burst pacing protocol was 
used. At each BCL, 40 stimuli were applied to reach steady state. Optical mapping movies 
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were recorded at steady state of each pacing BCL from both LV and RV epicardial surfaces 
of the heart. The background fluorescence was subtracted from each frame, and spatial (3 
x 3 pixels) and temporal (5 pixels) convolution filters were used. 
3.3.5 Data Analysis 
Both LV and RV optical mapping movies were used for data analysis. No 
significant differences were found between data from the two ventricles, and therefore, 
data was pooled for analysis.  
Action Potential Duration Measurements. Optical action potential duration was 
measured at both 50% and 80% repolarization (APD50 and APD80, respectively), and two-
dimensional (2D) APD maps were constructed to reveal the spatial distribution of APDs 
on the epicardial surface of the heart. Mean APD was obtained at different BCLs by 
averaging APDs from all pixels.  
Conduction Velocity Measurements. Local conduction velocity (CV) was 
calculated as described previously (Annoni et al., 2015; Smith et al., 2012). Specifically, 
the distributions of activation times (measured at (dV/dt)max) for the spatial regions of 5 x 
5 pixels were fitted with the plane, and gradients of activation times 𝑔𝑥  and 𝑔𝑦 were 
calculated for each plane along the x and y axes, respectively. The magnitude of the local 
CV was calculated for each pixel as (𝑔𝑥
2 + 𝑔𝑦
2)−1/2. 
APD Heterogeneity Measurements. The spatial dispersion of APD or dispersion of 
repolarization at both 50% and 80% repolarization was estimated based on the 
heterogeneity index, µ (Annoni et al., 2015; Smith et al., 2012): 
                                                   µ = 
(APD95%−APD5%)
APD50%
                       (1) 
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where APD95% and APD5% represent the 95th percentile and 5th percentiles of the APD 
distribution, respectively, and APD50% is the median of APD distribution.  
3.3.6 Statistical Analysis 
All data are presented as means ± standard errors of the mean. Statistical 
comparisons of APD, µ, and echocardiography data between Sham and VNS groups were 
performed using one-way ANOVA test (Origin Software, Northampton, MA, USA). 
Statistical comparison of echocardiographic assessment among Baseline, Week 2, and 
Week 9 were performed using a paired Student’s t-test. Comparison of CV were performed 
using a paired t-test. Values of p < 0.05 were considered to be statistically significant.   
3.4 Results 
3.4.1 Echocardiographic Assessments of Long-Term VNS 
To determine both the in vivo acute and chronic effects of VNS on cardiac 
performance in the healthy animals, LV function was assessed using echocardiography at 
both Weeks 2 and 9 after VNS implantation. As presented in Fig. 3.1, VNS rats exhibited 
similar EF as compared to Sham rats throughout the duration of the study. Furthermore, 
EF did not change significantly over time in both Sham and VNS rats. Measurements of 
fractional shortening were also made, and no significant differences were observed (data 
not shown).   
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Figure 3.1: Effects of long term intermittent VNS on left ventricular (LV) function. Mean 
ejection fraction (EF) (%) measurements from Sham and VNS rats for Baseline, Week 2, 
and Week 9. 
 
3.4.2 Effect of VNS on Ventricular APD 
Ex vivo optical mapping was used to probe action potential conduction and 
restitution dynamics in order to determine how long-term intermittent VNS modulates the 
basic electrophysiological properties of the healthy myocardium. Changes in APD were 
measured during periodic pacing at gradually decremented BCLs. Fig. 3.2(a,b) (top panels) 
show examples of 2D APD80 and APD50 maps, respectively, obtained at a BCL of 200 ms 
and 100 ms for both Sham and VNS-treated rats. The lower panels show corresponding 
traces of action potentials from a representative single pixel. Fig. 3.2(a) bottom panel 
compares VNS versus Sham traces at the same BCLs. APD from the VNS group is shorter 
than APD of the Sham group for BCL 200 ms, but not for 100 ms. Fig. 3.2(b) compares 
both VNS and Sham action potential traces that were recorded at different BCLs.  
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The change in APD of all VNS and Sham rats is shown in Fig. 3.3(a) for different 
BCLs. At higher BCLs (between 200 ms and 120 ms), the APDs of VNS rats (both APD50 
and APD80) were significantly lower than those of Sham rats. For instance, at BCL 200 ms, 
the APD80 and APD50 values for Sham rats were 70.69 ± 0.34 ms and 45.39 ± 0.84 ms, 
respectively. After VNS treatment, the APD80 and APD50 values of VNS rats were both 
significantly (p<0.05) reduced to 60.12 ± 2.16 ms and 29.81 ± 1.59 ms, respectively. This 
APD shortening effect disappeared at lower BCLs (between 100 ms and 80 ms). At BCL 
100 ms, the APD80 values for Sham and VNS rats were 63.98 ± 1.82 ms and 61.87 ± 0.22 
ms (p=NS), respectively. Furthermore, the APD50 values for Sham and VNS rats were and 
42.89 ± 1.42 ms and 37.22 ± 0.28 ms (p=NS).  
 
  
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Representative right ventricular (LV) action potential duration (APD) maps 
at basic cycle length (BCL) = 200 ms and 100 ms. A) Examples of APD80 maps with action 
potential traces from pixels “◆” and “◼” for BCLs = 200 ms and 100 ms, respectively. B) 
Examples of APD50 maps with representative action potential traces from pixels “” and 
“” for Sham and VNS, respectively. 
 
3.4.3 Effect of VNS on Ventricular APD Restitution Properties 
Calculation of the restitution properties of the heart (i.e. the change of APD as BCL 
decreases) showed that the APD of VNS rats (both APD80 and APD50) did not 
monotonically decrease as BCL decreased, in contrast to APDs of Sham rats (Fig. 3.3.(a)). 
Therefore, it was not feasible to fit the VNS data to a single curve and accurately calculate 
the slope of restitution curve for VNS rats, and we used an alternative approach, in which 
APD values at different BCLs were normalized to the APD value at BCL 200 ms for each 
individual rat. The mean normalized APD data for both Sham and VNS rats for APD80 and 
APD50 are shown in Fig. 3.3(b,c), respectively. Note that APD80 decreased as BCL 
decreases, showing normal restitution properties, both for VNS and Sham rats. However, 
the behavior of APD50 is different: the monotonic decrease of APD was observed for Sham, 
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but a biphasic change of APD, with initial increase and subsequent decrease, was observed 
in VNS rats. These data suggests that VNS affects the dynamic behavior of the heart for 
APD50, but not for APD80. 
 
 
 
 
 
 
Figure 3.3: Effects of long term intermittent VNS on APD. A) Mean APD50 and APD80 
values for both Sham and VNS at different BCLs. Normalized B) APD80 and C) APD50 
values to BCL 200. *, # Statistical significance (p < 0.05) between Sham and VNS for 
APD80 and APD50, respectively. 
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3.4.4 Effect of VNS on µ and CV 
To determine whether VNS affected the spatial dispersion of APD, we calculated 
the heterogeneity index µ at different BCL values for both APD50 and APD80. The µ values 
calculated for BCL 200 ms and 100 ms are shown in Fig. 3.4(a,b), demonstrating no 
significant differences in µ values between VNS and Sham at different BCLs. The values 
are similar for other BCLs (data not shown).  
To investigate the effect of VNS on action potential propagation in the ventricular 
myocardium surfaces, we constructed activation time maps illustrating action potential 
propagation for both Sham and VNS groups at various BCLs. Representative examples of 
2D activation time maps at BCL 100 ms is shown in Fig.  3.5(b). These maps show normal 
propagation in both VNS and Sham rats. Fig. 3.5(a) shows mean CV data at different 
BCLs. Chronic VNS significantly increased the mean CV of impulse propagation in the 
ventricles for all BCL (p<0.05). Specifically, by 23% for BCL 200 ms (from 0.676 ± 0.024 
m/s to 0.830 ± 0.039 m/s) and by 31% for BCL 100 ms (from 0.604 ± 0.026 m/s to 0.792 
± 0.045 m/s).  
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Figure 3.4: Effects of VNS on spatial dispersion of APD (μ). Mean μ values for A) APD80 
and B) APD50 for BCLs = 200 ms and 100 ms. 
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Figure 3.5: Effects of VNS on and conduction velocity (CV). A) Mean CV values at 
different BCL values. B) Representative examples of LV action potential activation maps 
for the epicardial surfaces of Sham and VNS rats at BCL = 100 ms. Isochrones for 
activation time maps are shown 3 ms apart. The red marker denotes pacing site. *Statistical 
significance (p < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
47 
 
3.4.5 VNS Prevents Ex Vivo Ventricular Arrhythmias 
The anti-arrhythmic effects of VNS on healthy hearts were assessed by measuring 
the inducibility of the hearts to cardiac arrhythmias during ex vivo programmed electrical 
stimulation. As shown in Fig, 3.6, sustained VF/VT was observed in 3/4 Sham rats; 
whereas none (0/3) of the VNS rats developed VF or VT.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Quantification of the number of rats exhibiting ex vivo ventricular 
fibrillation (VF) and tachycardia (VT) episodes during programmed stimulation. 
 
3.5 Conclusions and Discussion 
In this study, we investigated the effects of chronic, cyclic VNS on healthy rat 
hearts. The main findings of this paper are as follows: 1) 10 weeks of intermittent VNS 
produced beneficial electrophysiological changes to the heart, including reduction of APD 
at larger BCLs and an increase of CV at all BCLs; 2) VNS did not induce any detrimental 
effects to the heart: neither affecting the LV function of the heart verified via 
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echocardiography nor increasing the spatial dispersion of APD (μ); 3) VNS significantly 
affected the restitution properties of the heart at the APD50, but not at the APD80, levels; 4) 
VNS had anti-arrhythmic effects of VNS that has been previously only reported for 
diseased hearts (Annoni et al., 2015; Beaumont et al., 2015). These results support the 
beneficial effects of VNS even in the absence of autonomic imbalance. 
It is universally accepted that the autonomic nervous system, consisting of both the 
parasympathetic and sympathetic systems, plays an important role in regulating the 
function of the heart (De Ferrari and Schwartz, 2011; Hirsch et al., 1987; Schwartz and De 
Ferrari, 2011). In the last decades, an abundance of experimental and clinical evidence has 
shown that cardiovascular diseases are accompanied by an imbalance in the vagal-
sympathetic outflow to the heart. It has been demonstrated that the autonomic balance can 
be potentially restored through the electrical stimulation of the vagus nerve (Annoni et al., 
2015; Li et al., 2004; Premchand et al., 2015); however, not much is known about the 
effects of parasympathetic stimulation via VNS on healthy hearts where the sympathetic 
and parasympathetic nervous systems are in balance. This can be attributed to the early 
major belief that vagal fibers have sparse innervations and only play a limited role in 
ventricles. As histochemical evidence from several studies has now convincingly 
questioned this viewpoint (Coote, 2013; Hoover et al., 2004; Randall et al., 2003; Ulphani 
et al., 2010), it becomes increasingly important to gain a better and clearer understanding 
of the effects of VNS. This is especially true since VNS is now emerging as a promising 
neuromodulation therapy for HF due to positive results from multiple clinical trials, such 
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as the Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart 
Failure (ANTHEM-HF) (Premchand et al., 2015). 
Slowing of myocardial CV may increase the risk of cardiac arrhythmias (Gaztañaga 
et al., 2012). This is because a decrease in CV allows the creation of smaller wavelengths, 
thus facilitating the initiation and maintenance of reentry subsequent to creation of 
functional conduction block. Our data suggest that VNS is able to moderately increase CV. 
This increase can be attributed to the increase or further preservation of the gap junction 
protein, connexin-43 (Cx-43) expression in the myocardium (Sabbah, 2011). It has been 
shown in previous studies that VNS is able to preserve the expression of Cx-43 in a rat 
model of MI (Wu and Lu, 2011).  
Prolongation of the ventricular APD is a hallmark of HF (Shah et al., 2005). In 
cases of HF, APD prolongation allows for the myocardium to preserve its contractility by 
prolonging calcium channel opening. However, this compensatory APD prolongation also 
causes intracellular calcium overload, increasing the propensity for triggered arrhythmias 
and increased T-wave alternans (Shimizu and Antzelevitch, 1999). Furthermore, this 
significant APD prolongation is typically associated with an increase in dispersion of 
repolarization (Wang and Hill, 2010). In other words, increases in both of these parameters 
have been shown to be able to create an arrhythmogenic substrate. Our results suggest that 
long-term intermittent VNS therapy decreases APD during programmed electrical 
stimulation and does not induce spatial APD dispersion, thereby rendering the hearts less 
vulnerable to inducible tachyarrhythmia as shown in Fig. 3-6.  
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Indeed, in the settings of HF with the characteristics of APD prolongation and CV 
slowing, which may promote reentrant arrhythmias, our observed effects of APD 
shortening and CV acceleration may be able to explain the beneficial effects of VNS. This, 
however, may be different in healthy hearts. In fact, it is important to note that APD 
shortening induced by activation of acetylcholine-activated potassium channels has been 
widely used as an arrhythmia model (Machida et al. 2011; Cho et al. 2014), and CV slowing 
has been an anti-arrhythmic feature of Class I anti-arrhythmic drugs (Cha et al. 1996; 
Kirchhof et al. 1998). APD shortening and CV acceleration have opposite effects on the 
wavelength for reentry, i.e. wavelength is the product of APD and CV which both are 
measured at a particular BCL. The wavelength can be used as an indicator of arrhythmia 
propensity in structurally normal hearts (Smeets et al. 1986; Pandit & Jalife 2013).   
Finally, our results suggest that VNS may affect the restitution properties of the 
heart, specifically at the APD50 level, which may suggest an increase in intracellular 
calcium handling. Our findings seem to support recent findings where VNS treatment 
activates the ryanodine receptor 2 (RyR2) channels (Li et al. 2015) and increases both 
sarcoplasmic reticulum Ca2+ ATPase (SERCA2) and sodium-calcium exchanger (NCX1) 
protein expressions in a chronic HF rat model (Zhang et al. 2015). The activation of RyR2 
channels increases calcium release from the sarcoplasmic reticulum (SR) (systole) which 
SERCA2 will pump the calcium back to the SR (diastole). Taken together, VNS is able to 
increase the expression levels of RyR2 and SERCA2; thus, enhancing excitation 
contraction coupling and improving cardiac pump function. Nonetheless, additional 
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experiments will need to be performed to specifically determine which myocyte membrane 
ion channels are up-or downregulated by chronic VNS. 
There were limitations to this study. While we were able to demonstrate the effects 
of VNS on the electrophysiological properties of the healthy myocardium, no 
histochemical results from the ventricles were performed in parallel to confirm and/or 
investigate mechanisms. Another limitation is that an animal group with age-matched 
controls, i.e. that did not have an implanted stimulator and electrode, was not included in 
the present study. However, since the objective of our study was to directly investigate the 
effects of VNS, we removed the confounding factor of surgical procedure effects on 
electrophysiology by implanting non-functional stimulators in our Sham group. Hence, not 
including such a control group will not affect the interpretation of our results. The 
conclusions of our study are also limited by the small sample size of rats used. 
In conclusion, we demonstrate that the administration of chronic intermittent VNS 
induces electrophysiological changes to a normal, healthy rat heart; thus, rendering the 
hearts less vulnerable to inducible arrhythmias. These results also suggest that VNS does 
not require the existence of autonomic imbalance to generate its positive effects. 
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4.1 Chapter Synopsis 
Activation of the parasympathetic branch of the autonomic nervous system, carried 
primarily by the vagus nerve, slows heart rate (HR) and increases HR variability (HRV). 
Recently, vagus nerve stimulation (VNS) has gained attention as a potential 
neuromodulatory technique to therapeutically regulate cardiac physiology. Therefore, there 
is renewed interest in understanding the multiple downstream signaling pathways which 
may underlie these effects. Here, we investigated the impact of one such downstream 
effector, the G-protein-coupled inwardly-rectifying K+ (GIRK) channel, on the 
chronotropic effects of acute VNS in mice. We collected in vivo electrocardiogram (ECG) 
recordings from mice lacking GIRK channels either globally or selectively in the atria or 
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ventricle during VNS. VNS induced bradycardia and increased HRV in wild-type mice and 
mice lacking GIRK in the ventricle. Global and atrial ablation of GIRK channels 
significantly blunted both HR and HRV responses to acute VNS. Additionally, both mice 
with either global or atrial ablation of GIRK channels were resistant to arrhythmic episodes 
induced by VNS. These data suggest that atrial GIRK channels are dominant mediators for 
VNS-induced dynamic changes in HR, HRV, and arrhythmogenesis in in vivo mice hearts. 
4.2 Introduction 
The autonomic nervous system is comprised of two main branches, 
parasympathetic and sympathetic, which work antagonistically to maintain cardiovascular 
homeostasis (Gordan et al., 2015). Autonomic dysregulation, characterized by excessive 
sympathetic activation and diminished parasympathetic response, is central to the 
pathogenesis of cardiovascular diseases, such as heart failure and hypertension (Bibevski 
and Dunlap, 2011; Schwartz and De Ferrari, 2011). Hence, autonomic modulation 
approaches to increase parasympathetic activity have emerged as a potential therapeutic 
strategy. As parasympathetic innervation to the heart is primarily carried by efferent fibers 
of the vagus nerve, vagus nerve stimulation (VNS) has shown promise in treating 
cardiovascular diseases (Beaumont et al., 2015; Premchand et al., 2015; Xie et al., 2014). 
As a result, VNS has gained significant popularity in recent years and there is renewed 
interest in understanding the downstream mechanisms of its actions in the heart..  
Activation of the parasympathetic nervous system results in a decrease in heart rate 
(HR) and an increase in beat-to-beat variability, known as heart rate variability (HRV) 
(Ardell et al., 2015; Armour et al., 1975; Levy and Zieske, 1969; Libbus et al., 2017; Neely 
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and Urthaler, 1992; Thompson et al., 1998). Parasympathetic regulation of HR is mediated 
largely through the release of the neurotransmitter acetylcholine (ACh) which activates 
muscarinic M2 receptors (M2R), subsequently releasing inhibitory (Gi/o) G-proteins. 
Activation of these inhibitory G-proteins results in the dissociation of the  and  
subunits. The G subunit inhibits adenylyl cyclase activity which suppresses cAMP-
dependent signaling, inhibiting both the HCN channel (pacemaker or “funny” current, If) 
and L-type Ca2+ channel activity (DiFrancesco, 2010; DiFrancesco et al., 1989; 
DiFrancesco and Borer, 2007; Kozasa et al., 2018; Mangoni and Nargeot, 2008; Zaza et 
al., 1996). The  subunit activates the atrial G-protein gated inwardly rectifying K+ 
(GIRK) channel, often referred to as IKACh. The GIRK channel is a heterotetramer 
composed of two distinct homologous GIRK channel subunits: GIRK1 (Kir3.1) and GIRK4 
(Kir3.4) (Liang et al., 2014; Vorobiov et al., 2000; Wydeven et al., 2014). Activation of 
GIRK channels increases K+ efflux, resulting in membrane hyperpolarization which 
ultimately contributes to the slowing of pacemaker activity and sinus rate (Anderson et al., 
2018; Mesirca et al., 2016a; Wickman et al., 1998).  
The direct contributions of cardiac GIRK channel activity to the acute chronotropic 
effects of VNS have yet to be fully elucidated. Previous work has suggested, through 
methoxamine-induced parasympathetic activation in Girk4-/- mice, that approximately 50% 
of bradycardia elicited is GIRK dependent, while the other 50% is likely mediated via If or 
other currents (Wickman et al., 1998). Indeed, a recent study utilizing mice with 
knockdown of HCN4 show exaggerated responses to direct VNS (Kozasa et al., 2018). 
Since previous studies have shown that pharmacological manipulations do not consistently 
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recapitulate the effects of direct neuronal stimulation on cardiac electrophysiology (Mantravadi et 
al., 2007), the contributions of GIRK channel activation to the effects of direct VNS remain 
unclear. Here, we investigated the specific role of cardiac GIRK channels in mediating the 
chronotropic effects of VNS on the heart. This study is the first to evaluate the impact of 
GIRK channel ablation globally or selectively in the atrial or ventricular tissues on the 
chronotropic effects of direct VNS in mice in vivo.  
4.3 Materials and Methods 
All experiments were performed in accordance with the guidelines set forth by the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals and were 
approved by the University of Minnesota Institutional Animal Care and Use Committee 
(IACUC). 
4.3.1 Transgenic Murine Models 
Wild-type (C57BL/6J) mice were purchased from The Jackson Laboratory (Bar 
Harbor, ME, USA). The generation of Girk4-/- and MLC2VCre(+):Girk1fl/fl mice was 
described previously (Anderson et al., 2018; Wickman et al., 1998). Girk1fl/fl mice were 
crossed with SLNCre(+) mice (Nakano et al., 2011) to generate the SLNCre(+):Girk1fl/fl 
line. All transgenic mouse lines were bred, validated, and provided by Allison Anderson 
and Dr. Kevin Wickman. All mice were housed in a quiet, temperature- and humidity-
controlled room with a 12:12 hour light–dark cycle. Food and water were available 
ad libitum.  
4.3.2 Vagus Nerve Bipolar Cuff Electrode Implantation 
Mice were anesthetized with isoflurane (5% for induction and 1.5% for 
maintenance). After hair removal and skin cleaning, aseptic technique was used to make a 
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ventral midline incision in the neck, and the skin and muscles were retracted. After 
identifying and isolating the right vagus nerve, a custom helical lead bipolar cuff electrode 
(Cyberonics, USA) was implanted around the nerve. The electrode was then connected to 
the VNS pulse generator (Demipulse Model 103, Cyberonics, Inc., Houston, USA).  
4.3.3 In vivo ECG Recordings 
Electrocardiograms (ECG) were recorded from each anesthetized mouse (IX-ECG-
12, iWorx, USA). ECG electrodes were placed subcutaneously into the limbs. Mice were 
anesthetized with 1.5% isoflurane supplemented with an air mixture of 40% O2/60% N2 to 
sustain stable HR. Baseline ECG recordings were recorded for 2–10 min, at which point 
VNS was administered. 
The six different groups of mice (n = 45, 2 – 3 months old) of approximately equal 
numbers of both sexes were used in the VNS experimental protocol (Fig. 4.1). After 
collecting baseline ECG recordings, VNS (0.25 mA, 10 Hz, 500 µsec) was then 
continuously delivered for 1 min. For each mouse, several (1-5) stimulation runs (see 
below) were performed. Afterwards, atropine (Sigma Aldrich, USA, 2.0 mg/kg) was 
administered via intraperitoneal (IP) injection, and after a 10 min waiting period, 1-2 
stimulation runs were performed.  
Each stimulation run consisted of the following in-vivo ECG recordings (Fig. 4.1):  
(1) 1 min of baseline recording before VNS (PRE) 
(2) 1 min of recording during continuous VNS (ON) 
(3) 1 min of recording during recovery after VNS (POST) 
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Figure 4.1: Detailed schematic of the experimental stimulation run. VNS electrodes was 
placed around the cervical vagus nerve. VNS (0.25 mA, 10 Hz, 500 µsec) was administered 
continuously. Atropine (2.0 mg/kg) was injected IP to block the activity of the muscarinic 
receptors. Several (1-5) stimulation runs were collected which consists of PRE (baseline 
recording), ON (continuous VNS), POST (recovery). 
 
4.3.4 Data Analysis for In vivo ECG Recordings 
The in-vivo ECG recordings from all stimulation runs were used to quantify 
changes in the HR and HRV throughout the study using Kubios HRV 2.0 software 
(Tarvainen et al., 2014). All values were averaged over 1 min PRE, ON, and POST periods 
of VNS stimulation. Noisy data segments, premature atrial complexes (PACs), and arrhythmic 
episodes were excluded, and only steady-state data after initial adjustment of the HR to acute VNS 
were used for the analysis.  
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To account for variations in baseline HR, the chronotropic effect of VNS was determined 
by calculating a relative change in HR, ∆HRON, as the following: 
∆𝐻𝑅𝑂𝑁 = (
𝐻𝑅𝑂𝑁 − 𝐻𝑅𝑃𝑅𝐸
𝐻𝑅𝑃𝑅𝐸
) ∗ 100% 
where HRON and HRPRE are the mean HR during the VNS ON and PRE periods, 
respectively. 
To quantify the variation of beat-to-beat intervals, HRV was calculated as the ratio 
between the standard deviation of RR intervals to mean of RR intervals, as descried 
previously (McIntyre et al., 2014):  
𝐻𝑅𝑉 = (
𝑆𝐷𝑅𝑅
𝑀𝑒𝑎𝑛 𝑅𝑅
) ∗ 100% 
The number of mice that exhibited arrhythmic episodes were also quantified during 
both PRE and ON. An arrhythmic episode was defined as any of the following episodes: 
1) skipped beats, 2) bigeminy, 3) bradycardia (at least 25 bpm less than the mean PRE or 
ON HR and lasted for more than 2 s), and 4) tachycardia (at least 25 bpm more than the 
mean PRE or ON HR and lasted for more than 2 s).  PAC episodes were separated from 
all other arrhythmic events, as PACs can occur in healthy conditions and pose less threat 
to the heart than the other types of arrhythmias (Shindler and Kostis, 2009). 
4.3.5 Statistical Analysis 
All data are presented as mean ± SEM. A student’s t-test, 2-way ANOVA with 
repeated measures, and Fisher’s exact test were used as appropriate. For studies involving 
2-way ANOVA analysis, interaction is reported if one was detected. Post-hoc analysis 
(Bonferroni multiple comparison) was used when appropriate. The level of significance 
was set at P < 0.05.  
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4.4 Results 
4.4.1 Impact of GIRK ablation on basal regulation of HR and HRV 
As functional GIRK channels are present in both atrial and ventricular tissue 
(Coote, 2013; Harvey and Belevych, 2003; Kurachi et al., 1986; Lomax et al., 2003; 
Ulphani et al., 2010), we aimed to distinctively assess and compare the relative 
contributions of tissue specific GIRK channel in mediating the bradycardic effects of VNS. 
Hence, in addition to the SLNCre mice line, we also included a recently developed 
ventricular GIRK knockout mouse line which was generated by crossing Girk1fl/fl mice 
with the MLC2VCre line (Anderson et al., 2018). Prior to VNS protocol initiation, we 
recorded baseline HR and HRV values to investigate the consequences of GIRK channel 
ablation on HR regulation in vivo. We did not observe a difference in baseline HR or HRV 
between wild-type and Girk4–/– mice (Fig. 4.2(a,b)). Similarly, there were no significant 
differences in baseline HR and HRV between SLNCre(-):Girk1fl/fl and SLNCre(+):Girk1fl/fl 
littermates (Fig. 4.2(a,b)). Lastly, MLC2VCre(-):Girk1fl/fl and MLC2VCre(+):Girk1fl/fl 
mice displayed comparable baseline HR and HRV values (Fig. 4.2(a,b)). These results 
indicate that GIRK channel ablation did not cause a significant difference in resting mean 
HR and HRV. 
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Figure 4.2: Influence of GIRK channels on baseline HR and HRV. A) Summary of 
baseline HR data across genotypes. There were no significant differences between wild-
type (n=10) and Girk4-/- (n=10) mice (t18=1.0; P=0.32), SLNCre(-):Girk1fl/fl (n=6) and 
SLNCre(+):Girk1fl/fl  (n=5) littermates (t9=1.1; P=0.29), and MLC2VCre(-):Girk1fl/fl (n=6) 
and MLC2VCre(+):Girk1fl/fl (n=8) littermates (t12=0.7; P=0.51). B) Summary of baseline 
HRV data across genotypes. There were no significant differences between wild-type 
(n=10) and Girk4-/- (n=10) mice (t18=1.2; P=0.23), SLNCre(-):Girk1fl/fl (n=5) and 
SLNCre(+):Girk1fl/fl (n=5) littermates (t8=1.1, P=0.32), and MLC2VCre(-):Girk1fl/fl (n=6) 
and MLC2VCre(+):Girk1fl/fl (n=8) littermates (t12=0.32; P=0.76). 
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4.4.2 Contributions of GIRK channels to the acute effects of VNS on 
HR 
 We next sought to probe the consequences of GIRK channel ablation on the 
bradycardic effects of acute VNS by comparing the relative change in HR during VNS ON 
to PRE values (∆HRON). We observed pronounced VNS-induced bradycardia in wild-type 
mice (Fig. 4.3(c)). This dramatic HR decrease was significantly blunted in Girk4–/– (Fig. 
4.3(c)). Similarly, SLNCre(+):Girk1fl/fl mice displayed minimal VNS-induced HR 
reduction as compared to SLNCre(-):Girk1fl/fl mice (Fig. 4.3(a-c)). On the other hand, the 
VNS-induced HR decrease was comparable between MLC2VCre(+):Girk1fl/fl and 
MLC2VCre(-):Girk1fl/fl mice (Fig. 4.3(c)). Regardless of genotype, VNS POST values 
returned back to baseline PRE values after the cessation of VNS (data not shown). Next, 
to investigate if the chronotropic effects of VNS were dependent on activation of 
muscarinic receptors, atropine (2.0 mg/kg) was administered before the VNS protocol was 
run again after a 10 min waiting period. In the presence of atropine, the negative 
chronotropic effects of VNS were suppressed regardless of genotype (Fig. 4.3(d)). Overall, 
our results show that bradycardia induced by VNS in the mouse is almost entirely 
dependent on muscarinic activation of atrial GIRK channels.    
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Figure 4.3: Impact of GIRK channel ablation on the negative chronotropic effects of 
VNS. Representative raw ECG recording traces of anesthetized A) SLNCre(-):Girk1fl/fl and 
B) SLNCre(+):Girk1fl/fl mice at the following points of the VNS protocol: PRE (left) ON 
(middle) and  POST (right). Note the presence of small spikes on the ECG traces during 
the ON periods corresponding to VNS stimulation artifacts. C) Relative change in HR drop 
during VNS ON (∆HRON) for all genotypes prior to atropine administration. There is a 
significant difference in HR drop observed between wild-type (n=9) and Girk4-/- (n=10) 
mice (t17=6.5; P<0.001). Similarly, a significant difference in HR drop was observed 
between SLNCre(-):Girk1fl/fl (n=6) and SLNCre(+):Girk1fl/fl (n=5) littermates (t9=3.9; 
P<0.01). No significant difference was detected between MLC2VCre(-):Girk1fl/fl (n=6) and 
MLC2VCre(+)Girk1fl/fl (n=8) littermates (t12=0.95; P=0.36). Symbols: ***P<0.001 vs. 
wild-type; **P<0.01 vs. SLNCre(-)Girk1fl/fl mice. D) Relative change in HR drop during 
VNS ON (∆HRON) for all genotypes after atropine administration. There were no 
significant difference between wild-type (n=4) and Girk4-/- (n=6) mice (t8=0.6; P=0.59), 
SLNCre(-)Girk1fl/fl (n=6) and SLNCre(+)Girk1fl/fl (n=4) littermates (t8=0.2; P=0.82), and 
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MLC2VCre(-):Girk1fl/fl (n=6) and MLC2VCre(+):Girk1fl/fl (n=4) littermates  (t8=0.2, 
P=0.88). 
 
 
4.4.3 Influence of GIRK channels to the acute effects of VNS on HRV 
To assess how GIRK ablation impacts beat-to-beat variation in HR induced by 
VNS, we measured HRV during PRE and ON periods of VNS. During VNS ON, a 
significant increase in HRV was observed in wild-type mice (Fig 4.4(b)). This increase in 
HRV during VNS ON was significantly diminished in Girk4–/– mice (Fig 4.4(b)). 
Similarly, HRV increased during VNS ON in SLNCre(-):Girk1fl/fl control mice, but was 
absent in SLNCre(+):Girk1fl/fl mice (Fig 4.4(a-b)). HRV during VNS ON increased 
similarly in both MLC2VCre(-):Girk1fl/fl  and MLC2VCre(+):Girk1fl/fl mice (Fig 4.4(b)). 
Notably, atropine blocked the VNS-induced increase in HRV in all genotypes, 
demonstrating the dependence of this effect on muscarinic receptor activation (Fig 4.4(c)). 
These results indicate that the VNS-induced increase in HRV in mice is primarily mediated 
through activation of atrial GIRK channels. 
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Figure 4.4: Impact of GIRK channel ablation on VNS-induced HRV increase. A) 
Typical RR tachograms during VNS ON, comparing between the beat-to-beat changes in 
RR intervals between SLNCre(-):Girk1fl/fl  (top) and SLNCre(+):Girk1fl/fl  (bottom) mice. 
B) Summary of mean HRV data at PRE and ON VNS prior to atropine administration. 
Two-way ANOVA analysis revealed an interaction between genotype and treatment 
between wild-type (n=8) and Girk4-/- (n=10) mice (F1,16=20.3; P<0.001), and between 
SLNCre(-):Girk1fl/fl (n=6) and SLNCre(+):Girk1fl/fl (n=5) littermates (F1,9=12.8; P<0.01). 
There was a significant main effect of treatment (F1,12=44.0; P<0.001) between 
MLC2VCre(-):Girk1fl/fl (n=6) and MLC2VCre(+)Girk1fl/fl (n=8) littermates, but no main 
effect of genotype (F1,12=4.2; P=0.06) or interaction between genotype and treatment 
(F1,12=3.2; P=0.10). Symbols: *,**,*** P<0.05, 0.01, and 0.001, respectively, vs. PRE 
(within genotype); ###P<0.001, ON wild-type vs. Girk4-/-; ##P<0.01, ON SLNCre(-
):Girk1fl/fl vs. SLNCre(+):Girk1fl/fl. C) Summary of mean HRV data at PRE and ON VNS 
after atropine administration. There was no main effect of treatment or genotype (F1,8=2.0, 
P=0.19), or interaction between genotype and treatment (F1,8=3.2; P=0.11) between wild-
type (n=4) and Girk4-/- (n=6) mice. There was no main effect of treatment (F1,8=0.1, 
P=0.76) or genotype (F1,8=0.53, P=0.49), and no interaction between treatment and 
genotype (F1,8=3.5, P=0.1) between SLNCre(-):Girk1fl/fl (n=6) and SLNCre(+):Girk1fl/fl 
(n=4) littermates. There was no main effect of treatment (F1,7=0.45, P=0.52 or genotype 
(F1,7=0.79, P=0.40), and no interaction between treatment and genotype (F1,7=0.3; P=0.62) 
between MLC2VCre(-):Girk1fl/fl (n=6) and MLC2VCre(+)Girk1fl/fl (n=4) littermates. 
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4.4.4 Impact of GIRK channels on VNS-induced arrhythmias 
To explore the contributions of GIRK channels on VNS-induced arrhythmogenesis, 
we quantified arrhythmia occurrences (i.e., bigeminy, skipped beats, tachycardia, and 
bradycardia) during VNS ON (Fig. 4.5(a)). No mice displayed arrhythmic episodes prior 
to VNS (data not shown). However, arrhythmic episodes were commonly observed in wild-
type, SLNCre(-):Girk1fl/fl, MLC2VCre(+):Girk1fl/fl, and MLC2VCre(-):Girk1fl/fl mice 
during VNS ON (Fig. 4.5(b)). In contrast, both Girk4–/– and SLNCre(+):Girk1fl/fl mice 
were resistant to VNS-induced arrhythmias (Fig. 4.5(b)). Similarly, these arrhythmic 
episodes were no longer observed after atropine administration during VNS ON (data not 
shown). No significant difference in the number of mice exhibiting PACs was observed 
PRE (data not shown) or ON (Fig. 4.5(c)) across all genotypes, suggesting that GIRK 
channels do not play a major role in the formation of PACs. Overall, these findings suggest 
that atrial GIRK channels play a critical role in the induction of arrhythmias via VNS. 
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Figure 4.5: Role of GIRK channels in VNS-induced arrhythmias. A) Representative 
examples of anesthetized raw ECG recordings of arrhythmic (i.e., bigeminy, skipped beats, 
bradycardia, and tachycardia) and PAC episodes during VNS ON. B) Total number of mice 
exhibiting arrhythmic episodes during VNS ON. Fisher’s exact test revealed a significant 
difference in arrhythmia incidence between wild-type (n=10) and Girk4-/- (n=10) mice 
(P<0.01), and SLNCre(-)Girk1fl/fl (n=6) and SLNCre(+)Girk1fl/fl (n=5) littermates (P<0.05), 
but no difference between MLC2VCre(-):Girk1fl/fl  (n=6) and MLC2VCre(+):Girk1fl/fl (n=8) 
littermates (P=0.14). Symbols: **P<0.01 vs. wild-type; *P<0.05 vs. SLNCre(-)Girk1fl/fl. 
C) Total number of mice exhibiting PACs during VNS ON. Fisher’s exact test revealed no 
significant differences in PAC incidence between wild-type (n=10) and Girk4-/- (n=10) 
mice (P=0.65), SLNCre(-)Girk1fl/fl (n=6) and SLNCre(+)Girk1fl/fl (n=5) littermates 
(P=0.55), or MLC2VCre(-)Girk1fl/fl (n=6) and MLC2VCre(+)Girk1fl/fl (n=8) littermates 
(P=1.0). 
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4.5 Conclusions and Discussion 
VNS has received increased attention recently due to the potentially protective role 
it plays in various heart diseases (Beaumont et al., 2015; Premchand et al., 2015; Xie et al., 
2014). Yet, the underlying mechanisms by which VNS affects the heart remain to be fully 
elucidated. Cardiac cholinergic signaling is a complex biological phenomenon involving 
the interactions of several ion channels following the activation of muscarinic receptors 
after the release of ACh. Several pharmacological and genetic studies have suggested that 
GIRK channels, voltage gated Ca2+ channels, and the If current are all downstream effectors 
of muscarinic activation, each contribute to parasympathetic regulation of the heart 
(DiFrancesco et al., 1989; DiFrancesco and Borer, 2007; Liang et al., 2014; Mangoni and 
Nargeot, 2008; Mesirca et al., 2013; Vorobiov et al., 2000; Wickman et al., 1998; Zaza et 
al., 1996). However, the relative contributions of each of these ion channels have not been 
distinctively investigated. This study is the first to apply VNS on transgenic GIRK-
deficient mice, thereby specifically assessing the role of the muscarinic GIRK  signaling 
pathway in mediating the chronotropic effects of VNS in vivo. 
Previous reports have shown that Girk4-/- mice displayed blunted HR and HRV 
responses to the impact of pharmacological stimulation of the parasympathetic system 
(Mesirca et al., 2013; Wickman et al., 1998). Here, we observed that nearly all of the HR 
and HRV responses to electrical stimulation of the vagus nerve is absent in Girk4-/-. 
Furthermore, the administration of atropine yielded similar results, demonstrating the 
muscarinic dependence of this response. Thus, these results highlight that muscarinic- 
GIRK channel signlaing plays a significant role in the negative chronotropic effects of 
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VNS. Notably, studies have shown that functional GIRK channels are not only exclusively 
located in atria, but rather are also present in the ventricles (Coote, 2013; Harvey and 
Belevych, 2003; Kurachi et al., 1986; Liang et al., 2014; Lomax et al., 2003; Ulphani et 
al., 2010). Hence, we used mouse lines by which GIRK channels were selectively ablated 
in the ventricles (Anderson et al., 2018) and in the atria. Mice lacking GIRK channels 
selectively in atrial tissue recapitulated the striking lack of HR and HRV responses to VNS 
observed in the Girk4-/-mice. Taken together, our results strongly suggest that atrial GIRK 
channels are the main contributor in the parasympathetic regulation of HR induced by 
VNS.  
Nonetheless, the finding that almost all the HR and HRV effects of acute VNS can 
be attributed to atrial GIRK as the downstream effector is surprising. Given that there are 
data suggesting that other effectors should also play a significant role in modulating the 
chronotropic effects of parasympathetic stimulation in addition to GIRK channel activity 
(Mesirca et al., 2015, 2016b; Verkerk and Wilders, 2014). This could be due to the fact 
that we applied “high-level” VNS with our set of stimulation parameters. In fact, 
DiFrancesco et al showed an ACh concentration-dependent effect in activating If and IKACh 
in SA nodal cells: low doses of ACh in the nanomolar concentrations inhibits If while a 20-
fold higher concentrations are required to activate IKACh (DiFrancesco et al., 1989).  Hence, 
additional studies are warranted to quantify and correlate the level of ACh release with a 
given a set of VNS parameters.  
In addition to being used as a therapy to treat heart diseases (Beaumont et al., 2015; 
Premchand et al., 2015; Xie et al., 2014), VNS has also been used to induce and maintain 
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atrial fibrillation (AF) in large animal studies (Zhang and Mazgalev, 2011), and our results 
further highlight this pro-arrhythmic property. However, it is worth noting that there are 
important differences between the two applications. Both experimental and clinical VNS 
have been shown to be effective in treating heart failure when mild to moderate intensities 
are delivered, reducing HR by 10% or less (Zhang et al., 2009a). In contrast, VNS is 
arrhythmogenic when strong supra-threshold intensities are delivered, causing a significant 
HR reduction, as supported in this study (Akdemir and Benditt, 2016). In addition, this 
study further highlights the involvement of atrial GIRK channels specifically in mediating 
arrhythmia inducibility (Mesirca et al., 2016a), as none of our mice lacking GIRK both 
globally (Girk4-/-) and selectively in atrial tissue (SLNCre(+):Girk1fl/fl), exhibited 
arrhythmic episodes during VNS ON. Indeed, previous studies in mice have shown that 
Girk4 ablation confers resistance to pacing-induced atrial fibrillation (Kovoor et al., 2001). 
Additionally, GIRK4 ablation has also been shown to restore normal cardiac rhythm in 
mouse models of sick sinus syndrome and AV block (Mesirca et al., 2016a, 2016b). This 
study further highlights the clinical potential of targeting GIRK channels for the 
management of supraventricular arrhythmias. Furthermore, future experiments should be 
conducted to investigate intensities that correlate to GIRK activation which may guide 
clinicians to select VNS parameters that will induce minor HR reduction and deliver 
therapeutic benefits without arrhythmogenic risk. 
In summary, we conclude that muscarinic activation of atrial GIRK is a critical 
mediator in evoking the negative chronotropic and increased HRV effects of acute VNS in 
mice. Our findings also further highlight the role played by atrial GIRK in arrhythmia 
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inducibility and the potential of targeting this specific signaling pathway as a target for the 
management of atrial arrhythmias. 
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CHAPTER 5 DEVELOPMENT 
AND CHARACTERIZATION OF 
STOCHASTIC VNS ON ACUTE 
HEART RATE DYNAMICS 
 
(Published) 
S.W. Lee, K. Kulkarni, E. M. Annoni, I. Libbus, B.H. KenKnight, and E.G. Tolkacheva. 
“Stochastic vagus nerve stimulation affects acute heart rate dynamics in rats.” PLoS One. 
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5.1 Chapter Synopsis 
Vagus nerve stimulation (VNS) is an approved therapy for treatment of epilepsy and 
depression. While also shown to be promising in several preclinical and clinical studies to 
treat cardiovascular diseases, optimal therapeutic stimulation paradigms are still under 
investigation. Traditionally, parameters such as frequency, current, and duty cycle are used 
to adjust the efficacy of VNS therapy. This study explored the effect of novel stochastic 
VNS (S-VNS) on acute heart rate (HR) dynamics. The effect of S-VNS was evaluated in 
Sprague Dawley rats by comparing the acute HR and HR variability (HRV) responses to 
standard, periodic VNS (P-VNS) across different frequencies (FREQs, 10 – 30 Hz). Our 
results demonstrate that both S-VNS and P-VNS produced negative chronotropic effects 
in a FREQ-dependent manner with S-VNS inducing a significantly smaller drop in HR at 
10 Hz and 20 Hz compared to P-VNS (p<0.05). S-VNS demonstrated a FREQ-dependent 
drop in the SD1/SD2 ratio, a measure of HRV, which was absent in P-VNS, suggesting 
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that S-VNS may acutely modulate the nonlinear relationship between short- and long-term 
HRV. In conclusion, S-VNS is a novel stimulation procedure that may provide different 
physiological outcomes from standard P-VNS, as indicated by our analysis of HR 
dynamics. Our study provides a rationale for further detailed investigations into the 
therapeutic potential of S-VNS as a novel neuromodulation technique. 
5.2 Introduction 
  In recent years, there has been an emergence of interest in using neuromodulation 
techniques to enhance or suppress activity of the nervous system for the treatment of 
various pathological conditions, including but not limited to systemic inflammation, 
obesity, spinal cord injuries, and neurological disorders. One such therapy is vagus nerve 
stimulation (VNS), which was approved by the FDA as a clinical therapy for the treatment 
of refractory epilepsy in 1997 and for the treatment of medication-resistant depression in 
2005 (O’Reardon et al., 2006). As a result, VNS has become one of several non-
pharmacological treatment options to control epileptic seizures worldwide.  
The benefits of using VNS to treat cardiovascular diseases, including cardiac 
arrhythmias, heart failure (HF), hypertension, and myocardial ischemia, have been 
extensively explored in past decades, with several studies suggesting the therapy to be both 
safe and potentially effective as a long-term cardiac therapy (Annoni et al., 2015; Lee et 
al., 2016; Premchand et al., 2015; Xie et al., 2014). However, randomized clinical trials 
evaluating VNS in chronic HF patients have shown discrepant findings (Olshansky, 2016). 
While the INOVATE-HF and NECTAR-HF trials failed to demonstrate significant 
improvements, both ANTHEM-HF and the subsequent extension study (ENCORE) 
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yielded favorable and encouraging results including reduced HF symptoms and improved 
ventricular function (Gold et al., 2016; Nearing et al., 2016; Premchand et al., 2015; 
Zannad et al., 2015). In addition to different inclusion and exclusion criteria of HF patients, 
the different choice of stimulation parameters is another attributable factor for these mixed 
results.  
Traditionally, the therapeutic intensity of VNS is selected to demonstrate 
engagement of the autonomic nervous system (typically via observed changes in heart rate 
(HR)) (Yoo et al., 2016). The stimulation parameters used to treat cardiac diseases, 
however, are highly variable depending on different models and studies (Annoni et al., 
2015; Kong et al., 2012a; Li et al., 2004; Xie et al., 2014). Hence, there is an ongoing 
search for the optimal settings that will maximize the benefits of VNS. This can include 
the traditional approach of varying the stimulation frequency, current/voltage, and pulse 
width (Ardell et al., 2015; Kong et al., 2012a), as well as developing novel stimulation 
paradigms, such as the recently developed “microburst” VNS (Yoo et al., 2016). Typically, 
chronic periodic VNS (P-VNS) is applied, and its stimulation profile consists of 
administering periodic, repetitive electrical pulses with the level of stimulation (i.e. 
intensity) determined by a selected frequency, pulse duration, pulse amplitude, and duty 
cycle which all can be adjusted via radiofrequency communication link using a proprietary 
programming computer. In this study, we propose and evaluate an innovative stimulation 
technique: stochastic VNS (S-VNS). The version of S-VNS used in this study delivers 
electrical impulses to the nerve according to a Gaussian distribution of stimulation 
frequencies, instead of a constant frequency used in standard, P-VNS.  
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It is known that the cardiac beat-to-beat time intervals vary stochastically due to the 
inherent variability in HR (HRV). This variability can be attributed to many physiological 
factors including the influence of circadian rhythms, respiratory rhythms, temperature 
regulations, and others (Malik, 1996). In fact, it has been extensively reported that both 
increased HR and loss of HRV are associated with increased mortality in HF patients and 
are candidate markers for patients at risk of sudden cardiac death (Balasubramanian et al., 
2017; Hori and Okamoto, 2012). An abundance of literature supports that acute P-VNS 
effectively decreases HR and improves HRV via the extensive innervation of the vagus 
nerve into the sinoatrial (SA) and atrioventricular (AV) nodes (Kapa et al., 2016; Shen and 
Zipes, 2014). Even though the exact mechanisms responsible for the coupling between 
VNS and HR and HRV remains unclear, it is postulated that it is mediated through 
muscarinic receptor activation via the neurotransmitter acetylcholine (ACh) released at 
parasympathetic nerve terminals (Harvey and Belevych, 2003). However, while P-VNS 
may effectively modulate HR dynamics, there may exist a ‘physiological compensation 
mechanism’ in which the vagus nerve and the central-peripheral nervous system can adapt 
to the periodicity of the stimulation, a phenomena which can be similar to pharmacological 
tolerance (Buschman et al., 2006; Lund et al., 2011; Samniang et al., 2016). We propose 
that S-VNS might help to avoid this potential adaptation, and therefore, the goal of our 
study is to evaluate the influence of acute S-VNS therapy on instantaneous HR and HRV 
by using in-vivo rat hearts, and compare it to the standard P-VNS.   
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5.3 Materials and Methods 
Sprague-Dawley rats (n = 8, 250 – 400 g, Charles River Laboratories, Wilmington, 
MA) were used in this study. All experiments were performed in accordance with the 
guidelines set forth by the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals and were approved by the University of Minnesota Institutional 
Animal Care and Use Committee (IACUC). 
5.3.1 Vagus Nerve Bipolar Cuff Electrode Implantation 
Rats were anesthetized with isoflurane (5% for induction and 1.5% for 
maintenance). After hair shaving and skin cleaning, aseptic technique was used to make a 
ventral midline incision in the neck, and the skin and muscles were retracted. After 
identifying and isolating the right cervical vagus nerve and common carotid artery bundle, 
a custom 1.5 mm diameter helical lead bipolar cuff electrode (Cyberonics, USA) was 
implanted around the bundle. The right vagus nerve was chosen for this study because it 
primarily innervates the atria and the sinoatrial node, and thus, right-side stimulation may 
induce significant change in cardiac rhythm (Muppidi et al., 2011). The electrode was then 
connected to a battery-driven, constant current stimulator (Stimulus Isolator, model A385, 
World Precision Instruments, USA). At the end of the study, the anesthetized rats were 
euthanized by thoracotomy followed by heart explantation. 
5.3.2 VNS Protocols and Study Design 
Both P-VNS and S-VNS were continuously delivered for 2 minutes at a pulse 
duration of 500 µsec and an output current of 1.0 mA (Annoni et al., 2015; Lee et al., 2016; 
Xie et al., 2014). The same number of stimuli was used for both P-VNS and S-VNS.  
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P-VNS was delivered at different frequencies (FREQ) of 10, 20, or 30 Hz that were 
kept constant throughout the 2 minutes of stimulation. 
S-VNS was used with stochasticity (STOCH) of 10% or 20%. Three values of mean 
FREQ (i.e. 10, 20, and 30 Hz) were used similar to P-VNS, and STOCH (using a Gaussian 
distribution) was incorporated as:  
FREQSTOCH =
FREQ
1 ± [FREQ ∗ δ(STOCH)]
 
where δ(STOCH) is a random number with a mean of zero and a standard deviation of 
STOCH/FREQ. A custom LabView program was used to generate δ(STOCH) for each 
pulse. 
The detailed study design is shown in Fig. 5.1. Briefly, the vagus nerve was first 
stimulated at FREQ = 20 Hz, starting with P-VNS (P-VNS #1) followed by S-VNS with 
STOCH = 20% after a 1-minute stabilization interval. After completion, a similar run was 
conducted for a FREQ = 30 Hz which was followed by a run at FREQ = 10 Hz. After a 10-
minute stabilization interval, both P-VNS (P-VNS #2) and S-VNS with STOCH = 10% 
runs were conducted in the FREQ order of 20, 30 and 10 Hz. Each protocol for a certain 
FREQ consisted of the following stimulation: 
(4) 2 minutes of baseline recording before VNS (PRE) 
(5) 2 minutes of continuous VNS (ON) 
(6) 2 minutes of recovery after VNS (POST) 
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Figure 5.1: Detailed schematic of the experimental VNS protocol. Standard P-VNS or S-
VNS with different degree of stochasticity (STOCH, 10% and 20%) was administered 
across different frequencies (FREQ, 20, 30, and 10 Hz) with stabilization times between 
protocols and conditions. P-VNS, periodic vagus nerve stimulation; S-VNS, stochastic 
vagus nerve stimulation; STOCH, stochasticity; PRE, baseline recording; ON, continuous 
VNS; POST, recovery.    
 
5.3.3 Data Analysis for In Vivo ECG Recordings 
Electrocardiogram (ECG) was recorded from each anesthetized rat (IX-ECG-12, 
iWorx, USA). ECG electrodes were placed subcutaneously into the limbs. For both P-VNS 
and S-VNS, PRE, ON, and POST ECG data were recorded for 2 minutes. The in-vivo 
ECG recordings were used to quantify changes in the HR and HRV throughout the study 
using Kubios HRV 2.0 software (Tarvainen et al., 2014). Noisy data segments and ectopic 
beats were excluded and steady-state data after adjustment of the HR to acute VNS were 
used for the analysis. Hence, all runs of PRE, ON, and POST for all animals consisted of 
~1-minute and 40 seconds interval for analysis.   
78 
 
To account for variations in baseline HR, the chronotropic effect of VNS was 
determined by calculating a relative change in HR, ∆HRON, as the following: 
 
∆𝐻𝑅𝑂𝑁 = (
𝐻𝑅𝑂𝑁 − 𝐻𝑅𝑃𝑅𝐸
𝐻𝑅𝑃𝑅𝐸
) ∗ 100% 
 
 
where HRON and HRPRE are the mean HR during the VNS ON and PRE periods, 
respectively. 
After the termination of VNS, we assessed the recovery of HR to HRPRE baseline 
value. Therefore, the HR post-VNS ratio (HRPOST Ratio) was calculated as  
𝐻𝑅𝑃𝑂𝑆𝑇 𝑅𝑎𝑡𝑖𝑜 = |
∆𝐻𝑅𝑃𝑂𝑆𝑇
∆𝐻𝑅𝑂𝑁
| 
 
and 
 
∆𝐻𝑅𝑃𝑂𝑆𝑇 = (
𝐻𝑅𝑃𝑂𝑆𝑇 − 𝐻𝑅𝑂𝑁
𝐻𝑅𝑂𝑁
) ∗ 100% 
 
where HRPOST is the mean HR during the VNS POST period. A HRPOST Ratio = 1 means that 
the HRPOST returned to the baseline HRPRE value. Whereas, if HRPOST Ratio < 1 (or > 1), then 
the HRPOST was less (or greater) than the baseline HRPRE value. 
To quantify HRV, Poincaré plots were used to provide a two-dimensional 
representation of the correlation between successive RR intervals, as described previously 
(Tarvainen et al., 2014). Briefly, the spatial distribution of all points was fitted to an ellipse 
with the center coinciding with the average RR interval. The two dispersions 
(perpendicular (SD1) and parallel (SD2) to the line of identity y = x) and their ratio, 
SD1/SD2, were then calculated. Previously, it was established that SD1 is a measure of the 
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short-term HRV, while SD2 provides an assessment of both the short- and long-term HRV 
(Brennan et al., 2001; Tarvainen et al., 2014).  
5.3.4 Statistical Analysis 
All data are presented as means ± standard error. Statistical analyses were 
performed using Origin 9.1 software (Northampton, MA). Statistical comparisons were 
performed using a one-way ANOVA with repeated measures: 1) FREQ-dependent effect 
of P-VNS and S-VNS, 2) between S-VNS and P-VNS; 3) between the two P-VNS 
protocols, and 4) FREQ-dependent effect on SD1/SD2 for PRE, ON, and POST. A one 
sample t-test was performed to assess if the mean of the HRPOST Ratio is equal to one. Values 
of P < 0.05 were considered to be statistically significant. If appropriate, post hoc 
comparisons with Tukey’s test were performed, with P-values corrected for repeated 
comparisons.  
5.4 Results 
Fig. 5.2 shows typical examples of ECG traces during P-VNS (Panel A) and S-
VNS for STOCH = 10% and 20% (Panels B and C, respectively). Note the presence of 
small spikes on the ECG traces during the VNS ON periods corresponding to VNS 
stimulation artifacts, and the VNS-evoked decrease in HR. Furthermore, note the periodic, 
repetitive pattern of the VNS artifacts during P-VNS, and the absence of periodicity of the 
artifacts during S-VNS. 
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Figure 5.2: ECG Recordings and Corresponding HR Responses. Representative 
segments of ECG recordings and corresponding heart rate (HR) response for an 
anesthetized rat for PRE, ON, and POST during (A) P-VNS, (B) S-VNS (10%), and (C) 
S-VNS (20%) of the right cervical vagus nerve. Zoomed-in snapshots of PRE (black), ON 
(red), and POST (yellow) highlights VNS artifacts during stimulation. Here, VNS was 
continuously delivered at 20 Hz, 500 µs pulse width, and 1.0 mA for 2 minutes. 
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5.4.1 FREQ-dependent Chronotropic Effects of P-VNS and S-VNS 
The FREQ-dependent chronotropic effects of P-VNS and S-VNS are shown in Fig. 
5.3. Note that the reported mean and SEM of the P-VNS protocols were averages of the P-
VNS protocols (i.e., mean of the average of P-VNS #1 and P-VNS #2 protocols, n = 8). 
Relative changes in HR, ∆HRON, in response to VNS across FREQ ranging from 10 to 30 
Hz are shown for P-VNS (Panel A) and S-VNS (Panels B, C). For both P-VNS and S-VNS 
(both STOCH = 10% and 20%), no significant reduction in HR was observed as FREQ 
was increased from 10 Hz to 20 Hz. However, further increase of FREQ to 30 Hz produced 
a significant drop in HR. 
It has been shown in several species such as dogs (Parker et al., 1984) and rats 
(Berntson et al., 1992) that VNS FREQ is linearly related to heart period, while the relation 
to HR is nonlinear. To account for this possibility, we also calculated the relative changes 
in heart period for both VNS protocols. Fig. 5.3 (Panels D-F) indicate that FREQ-
dependent chronotropic effect for heart period is similar to the one for HR (compare to Fig. 
5.3, Panels A-C). 
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Figure 5.3: Effects of VNS FREQ on HR and Heart Period. Mean percent drop in HR 
for (A) P-VNS, (B) S-VNS (10%), and (C) S-VNS (20%) at different FREQ. Mean percent 
drop in Heart Period for (D) P-VNS, (E) S-VNS (10%), and (F) S-VNS (20%) at different 
FREQ. Note data reported here for P-VNS is the mean and SEM of the average of P-VNS 
#1 and P-VNS #2 protocols (n=8). (*p < 0.05) 
 
5.4.2 Effect of STOCH on HR and HRV 
The relative changes in HR, ∆HRON, in response to 10% (Panel A) and 20% S-VNS 
(Panel B), respectively, compared to its immediate preceding P-VNS at different FREQs 
are shown in Fig. 5.4. Overall, S-VNS had significantly smaller negative chronotropic 
effect relative to P-VNS at FREQ = 10 and 20 Hz. At 30 Hz, however, this reduced effect 
was eliminated as all the protocols exhibited similar relative drop in HR. Moreover, note 
that both P-VNS runs, P-VNS #1 and P-VNS #2, exhibited similar drop in HR at different 
FREQs, as indicated in Panel C, suggesting the stability of the experimental conditions 
over time. To investigate whether the order of application of P-VNS and S-VNS protocols 
contribute to the effects shown in Panels A and B, 20% S-VNS was compared to its 
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subsequent P-VNS #2 at different FREQs. Fig. 5.4(d) demonstrates similar effect in the 
relative change in HR responses when compared to Panels A and B, indicating that the 
effect is attributed to the S-VNS protocol itself, but not the different permutation of the two 
stimulation protocols.  
Representative Poincaré plots of both P-VNS (Panel A) and S-VNS (Panel B) and 
their quantitative assessment, SD1/SD2 (Panel C) are shown in Fig. 5.5. While our results 
suggest that S-VNS did not significantly affect SD1/SD2 when compared to P-VNS (as 
indicated in Fig. 5.5(c)), we observed a FREQ-dependent effect. As shown in Fig. 5.5(c), 
for P-VNS protocol, the SD1/SD2 values were similar for all FREQs for PRE, ON, and 
POST periods. Similarly, no significant difference in SD1/SD2 values was observed for 
S-VNS for PRE and POST periods. However, for VNS ON period, S-VNS showed 
significant reduction in SD1/SD2 values between FREQ = 10 Hz and 30 Hz. In addition to 
Poincaré analysis, we also evaluated HRV as a ratio of the standard deviation of RR interval 
(SDRR) to mean RR interval (mean RR), as described previously (McIntyre et al., 2014). 
From this approach, no significant difference was observed for all FREQs for PRE, ON, 
and POST periods for all VNS protocols (Fig. 5.6).  
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Figure 5.4: Effects of STOCH on the chronotropic effects of VNS. Mean percent drop in 
HR for (A) S-VNS (10%) and (B) S-VNS (20%) being compared to its immediate 
preceding P-VNS protocol at different FREQ. (C) Comparison of mean relative drop in 
HR between P-VNS protocols and (D) S-VNS (20%) and its subsequent P-VNS protocol 
at different FREQ. (*p < 0.05) 
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Figure 5.5: Effects of VNS on HRV using Poincaré analysis. Representative Poincaré 
plots of (A) P-VNS and (B) S-VNS (10%) during VNS stimulation (ON) at 10 Hz and 30 
Hz demonstrating the elliptical fitting of the beat-distribution cloud and the standard 
deviation of short-term (SD1) and long-term (SD2) variability. (C) Mean SD1/SD2 ratio 
for PRE, ON and POST across different FREQ. (*p < 0.05) 
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Figure 5.6: Effects of VNS on HRV using Time-Domain analysis. HRV was calculated 
as a ratio of the standard deviation of RR interval (SDRR) to mean RR interval (mean RR), 
as described previously (McIntyre et al., 2014). From this approach, no significant 
difference was observed for all FREQs for PRE, ON, and POST periods for all VNS 
protocols. 
 
 
To evaluate the recovery of HR to baseline values after VNS application, HRPOST 
Ratio was calculated across different FREQs. Our results from Panels B-D in Fig. 5.7 
indicate that for FREQ = 30 Hz, the HR could recover back to its PRE value in S-VNS 
protocols. However, for FREQ = 10 or 20 Hz, the HRPOST Ratio was less than 1, reflecting a 
persistent reduction in HR after the end of the VNS cycle. 
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Figure 5.7: Effects of VNS FREQ on HR recovery. (A) Schematic representation of 
different scenarios of HR recovery based on the value of HRPOST Ratio. Mean HRPOST Ratio 
values for (B) P-VNS, (C) S-VNS (10%), and (D) S-VNS (20%) at different FREQ. # 
p<0.05 compared to a mean theoretical value of 1. 
 
5.5 Conclusions and Discussion 
The aim of the present study was to develop and test a new autonomic modulation 
stimulation protocol using stochastic stimulation (S-VNS), and compare it with traditional 
stimulation waveforms (P-VNS).  
It has been well-established that an important feature of the adverse 
pathophysiological changes seen in HF is autonomic imbalance, characterized by 
sympathetic hyperactivation and parasympathetic withdrawal (De Ferrari et al., 2011). 
VNS has emerged as a promising therapy to normalize parasympathetic activation of 
cardiac control and restores normal levels of autonomic regulatory function. In fact, several 
animal studies suggest VNS exhibits both anti-arrhythmic and anti-inflammatory effects 
and attenuates myocardial damage and cardiac myocyte apoptosis (Annoni et al., 2015; Li 
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et al., 2004; Xie et al., 2014). Based on the encouraging results of the preclinical studies, 
several clinical VNS studies have been conducted. Both ANTHEM-HF and the subsequent 
extension study (ENCORE) yielded favorable and encouraging results as patients who 
received VNS experienced significant improvements in left ventricular (LV) structure and 
function, decreased HF symptom expression and decreased T-wave alternans, a measure 
of electrical instability (Nearing et al., 2016; Premchand et al., 2015). However, other 
randomized clinical trials, such as the INOVATE-HF and NECTAR-HF, failed to 
demonstrate significant improvements in clinical outcomes owing to imperfect 
inclusion/exclusion criteria and sub-therapeutic VNS dosing in significant (~30-50%) of 
the enrolled population (Gold et al., 2016; Zannad et al., 2015). Yet despite these and other 
studies, there still does not exist a universally accepted published prospective stimulation 
paradigm, which further highlights the importance and complexity of parameter 
optimization. Hence, to further optimize and improve VNS efficacy, this study introduced 
S-VNS, a novel technique that stimulates the vagus nerve stochastically since it is clinically 
well-established that healthy hearts have been associated with high HRV (Malik, 1996).  
Our study demonstrated a FREQ-dependent reduction in HR as a result of VNS, 
which was previously shown in several studies asserting that increasing the stimulation 
FREQ alters the rate of propagation of action potential through the vagus nerve fibers 
(Ardell et al., 2015).  However, we also observed that the drop in HR is significantly 
smaller for S-VNS as compared to P-VNS, even though mean FREQ was similar for both 
techniques. One of the possible reasons for this is that although the same number of stimuli 
were applied during both stimulation techniques, stimuli during S-VNS were distributed 
89 
 
more randomly. In P-VNS, there was a consistent number of stimuli being delivered 
between RR intervals, as highlighted in Fig. 5.2.  
In order to determine the residual functional effects occurring after cessation of 
VNS, we calculated HRPOST Ratio. Our results show that the post HR of both S-VNS and P-
VNS at certain FREQs did not return to baseline. This could be attributed to the fact that 
we applied continuous stimulation which is much longer than the typical intermittent VNS 
(e.g. duty cycle of 10% or 20%). Therefore, while other studies report a recovery to 
baseline at end of their intermittent stimulation (Ardell et al., 2015; Nearing et al., 2016), 
continuous stimulation may require more than the collected 2 minutes POST for the HR 
to return to baseline. Another possible explanation is that the cardiac effects of VNS may 
persist beyond the end of stimulation, and exhibit a “memory effect,” a phenomenon 
similar to cardiac memory. Cardiac memory is an established property of paced cardiac 
myocytes to reflect the influence of pacing history and adapt and respond to novel stimuli. 
Several experimental studies and numerical simulations have shown that memory plays a 
role in modulating cardiac dynamics (Libbus and Rosenbaum, 2002; Tolkacheva, 2007). 
Indeed, in future studies, we will examine post-VNS recovery after a longer time delay.   
In this study, we performed both linear and nonlinear approaches to evaluate the 
effects of VNS on HRV. Poincaré plots of RR intervals is a nonlinear approach used to 
monitor autonomic changes by means of SD1 and SD2. Physiologically, SD1 is an index 
of instantaneous recording of the beat-to-beat variability and reflects primarily the 
parasympathetic input to the heart, while SD2 is an index of long term variability which 
reflects the overall variability influenced by both the parasympathetic and sympathetic 
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contributions (Brennan et al., 2001; Libbus et al., 2017). Hence, their ratio (SD1/SD2) 
provides a measurement between both short term and long-term variability in the RR 
intervals. Libbus and colleagues recently reported that patients in the ANTHEM-HF trial 
who received chronic, right-sided intermittent P-VNS expressed an increase in the 
SD1/SD2 ratio, which suggested that right-sided VNS increases the balance in favor of 
parasympathetic dominance over sympathetic activity (Libbus et al., 2017). While our 
acute P-VNS did not induce any changes in SD1/SD2 ratio in rats, our experiments 
demonstrated that acute continuous S-VNS significantly decreased this ratio, specifically 
between 10 Hz and 30 Hz. We also observed no difference in SD1 and SD2 values with 
increase in stimulation FREQ across PRE, ON, and POST for P-VNS and S-VNS (Fig. 
5.8). This data suggests that FREQ and STOCH not only play a role in the chronotropic 
effects of VNS, but also in the engagement of the autonomic nervous system via relative 
difference in ACh release between the two VNS techniques. Nonetheless, it is worth noting 
that brief changes in HRV, i.e. during VNS ON phase, may or may not have any significant 
effects on clinical outcomes, and will need to be further investigated. While Poincaré maps 
suggest a change in autonomic activity, our ratio of SDRR to mean RR saw no significant 
HRV difference induced by both S-VNS and P-VNS (S1 Fig).  Indeed, there are several 
metrics to gauge autonomic activity which include time-domain (e.g. SDNN, RMSSD,…), 
frequency-domain (e.g. LF, HF, LF/HF,…), and nonlinear (Poincaré, sample entropy, 
detrended fluctuation analysis,…) methods (Shaffer and Ginsberg, 2017). Although 
previous studies have shown a possible correlation between the different measures (Guzik 
et al., 2007; Shaffer and Ginsberg, 2017), an exact equivalence has not been reported. It is 
91 
 
possible that Poincaré plots may detect abnormalities that are not as easily detectable with 
traditional time-domain measures, given that each parameter has different sensitivity to 
noise and other experimental conditions (Stapelberg et al., 2018). Hence, further 
investigations to fully uncover and understand the physiological relevance of these 
autonomic assessment methods are warranted in order to determine the efficacy of the 
different metrics in accurately quantifying autonomic activity. 
 
 
Figure 5.8: Values of SD1 and SD2. Mean (A) SD1 and (B) SD2 values for PRE, ON, 
and POST across different FREQs. No significant difference in SD1 and SD2 values were 
observed with increase in stimulation FREQ across PRE, ON, and POST for P-VNS and 
S-VNS. 
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In the present study, we observed a smaller drop in HR and a reduction in SD1/SD2 
ratio in S-VNS compared to P-VNS. From a physiological standpoint, this was a surprising 
finding since applying S-VNS does not necessarily correlate to stochastic release of ACh 
and stimulation of the muscarinic receptors of the cardiomyocytes. Rather, the efferent 
vagal fibers which are responsible for carrying descending information from the brain to 
the heart do not directly synapse with cardiomyocytes but rather with the intrinsic cardiac 
nervous system (ICNS), which acts as a buffer to register and send commands to the 
cardiomyocytes (Ardell et al., 2015). The ICNS is comprised of an intricate network of 
ganglia (and its neurons) that can independently act or communicate with its counterparts 
in the intrathoracic extracardiac, brain stem, spinal cord, and cortex to regulate intracardiac 
reflexes (Ardell et al., 2015). Although detailed studies will need to be performed to 
quantify the level of ACh release during the two stimulation protocols, we hypothesize that 
the observed minimal HR drop can be due to the fact that the temporal summation of ACh 
release is lower during S-VNS when compared to P-VNS protocol. This could be due to 
the fact that the instantaneous, effective FREQ of stimulation during S-VNS protocol is 
different (either less or more) from the corresponding FREQ of P-VNS protocol. 
Phase response curves (PRC) detail how a system with its own intrinsic properties 
evolve with an external perturbation. The heart is an example of such dynamical systems 
that when given an external stimulus can cause either phase mismatch or entrainment. It 
has been well established that the chronotropic response to vagal stimulation is phase-
dependent (Abramovich-Sivan and Akselrod, 1998). In fact, depending on the timing, 
duration, and magnitude of the vagal pulse, repetitive vagal stimulation has been shown to 
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be able to regulate the SA cells to beat at rates that are different from its intrinsic cycle 
length (Yang et al., 1984). Therefore, another possible explanation for our findings is that 
incorporating STOCH in our VNS may affect the level of entrainment between the vagal 
stimuli and the cycle length of the SA cells. Future additional studies should be conducted 
to understand how S-VNS may affect the intrinsic PRC. 
There has been an emerging interest in using closed-loop neuro-stimulation to 
achieve targeted control of cardiac parameters (Ugalde et al., 2014). In fact, significant 
developments have been made in this area based on state transition models where an 
algorithm optimally selects the VNS parameters to regulate instantaneous HR 
synchronously with cardiac cycles (Romero Ugalde et al., 2017). We hypothesize that 
incorporating STOCH in closed-loop VNS may potentially lead to improved therapeutic 
efficacy. Physiologically, the heart rhythm is not deterministic and is known to exhibit 
beat-to-beat variability (HRV) caused by numerous physiological factors including the 
influence of circadian rhythms, respiratory rhythms, temperature regulations, and others 
(Dvir and Zlochiver, 2013). In fact, it has been associated that low HRV is a predictor for 
pathological cardiac conditions (Balasubramanian et al., 2017). Hence, we hypothesize that 
by recording real-time changes in HRV and then integrating this “inherent stochastic 
feedback” into the stimulation of the VNS through STOCH may lead to a more 
physiological stimulation of the vagus and increase the efficacy of VNS to treat cardiac 
disease. This will require a fully functional, implantable, and chronic version of the S-VNS 
system that has real-time monitoring capabilities   
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One of the limitations of our study is that we only investigated the differences 
between P-VNS and S-VNS with respect to HR and HRV, and used a healthy rat model. 
Furthermore, we only evaluated the acute effects. Beneficial effects have been observed 
when chronic P-VNS was applied in both healthy and diseased conditions (Annoni et al., 
2015; Lee et al., 2016; Li et al., 2004; Nearing et al., 2016); therefore, additional chronic 
studies in both healthy and diseased conditions need to be performed in order to evaluate 
the full potential of S-VNS.  
Moreover, our results suggest that S-VNS may enable some flexibility in nerve 
response by its ability to vary the stimulation intervals and providing a ‘pseudo-
intermittent’ stimulation. Therefore, even though the same mean FREQ in both P-VNS and 
S-VNS were delivered, S-VNS had a smaller drop in HR. This could make S-VNS suitable 
for treatment of diseased conditions such as hypertension, where a controlled drop in blood 
pressure with a minimal change in HR are desired. This study suggests that incorporating 
STOCH may provide room for titration of other stimulation parameters (i.e. duty cycle and 
output current). In fact, in terms of treatment of brain disorders, non-periodic stimulation 
is currently being studied in the preclinical setting with promising results. Examples of 
stochastic neuromodulation techniques include but not limited to stochastic galvanic 
vestibular stimulation and transcranial random noise stimulation (Goel et al., 2015; van der 
Groen and Wenderoth, 2017). Therefore, there is the potential for S-VNS to induce changes 
in physiological parameters other than HR and HRV, making it a plausible candidate to 
improve current VNS treatment for epilepsy and depression, but this will require more in-
depth investigation.  
95 
 
Furthermore, it is well accepted that the cervical vagus nerve is composed of both 
myelinated A and B fibers and unmyelinated C fibers (Yuan and Silberstein, 2016a), and 
our study does not address the question as to which fibers are indeed stimulated. Zagon et 
al have demonstrated that providing higher stimulation amplitudes, i.e. 200 µA, activates 
both unmyelinated and myelinated fibers in anesthetized rats (Zagon and Kemeny, 2000). 
Hence, this suggests that our stimulation current of 1 mA is sufficient to activate the whole 
thin vagal trunk of our rats. However, the discharge frequencies between afferent and 
efferent fibers may be different, and thus, future studies are needed to determine whether 
the mechanisms of both P-VNS and S-VNS occurs primarily through the afferent or 
efferent pathways. 
 Another limitation of our study is that the sequence testing was not randomized. 
However, we did not monotonically increase our FREQ from 10 Hz to 30 Hz. Instead the 
sequence order was 20 Hz, 30 Hz, and 10 Hz, but nonetheless, there may be the potential 
of order effects. Finally, the ECG recordings from rats were obtained with the use of 
general anesthesia, which is known to affect the HR of animals as compared to conscious 
animal ECG telemetry recordings. In fact, it has been reported that high-dose isoflurane 
can suppress the central cardiac parasympathetic activity in rats (Toader et al., 2011; Yang 
et al., 2014). As a result, we ensured that the dosage of isoflurane administered was low 
(~1.5%) and remained identical across all rats throughout the duration of the study; 
therefore, it should not affect the interpretation of our results.  
Due to the long duration of the experimental procedures, we only tested the effect 
of STOCH values of 10% and 20% in this present manuscript. Additional experiments will 
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need to be performed to explore the full range of STOCH values. Furthermore, we also 
applied fixed values of current amplitude and pulse width. It is well accepted that VNS 
would elicit an immediate change in HR correlating with VNS current amplitude and pulse 
width (Nearing et al., 2016). Hence, while a different magnitude drop in HR value may be 
observed, our interpretation of the effects of incorporating STOCH should not be affected. 
In addition, while we only observed a difference of 2% HR drop between P-VNS and S-
VNS which means extrapolating this to human may make these changes negligible, it is 
worth noting that the average HR of healthy rats is roughly 300 – 350 bpm which is about 
five times faster than the average resting HR of humans (Azar et al., 2011; Yang et al., 
2014). Therefore, we propose these exploratory findings to first be confirmed in larger 
animal studies under both control and diseased conditions before being tested in humans. 
Nevertheless, we plan to further evaluate the robustness and efficacy of our proposed S-
VNS in chronic future studies and on non-anesthetized murine models.  
In conclusion, thethe evoked chronotropic response to P-VNS (delivered at a 
constant FREQ of 10, 20, or 30 Hz) were evaluated, and compared to S-VNS where 
stochastic variability was imposed in delivered FREQs with constraints for 10% or 20% 
around these three FREQs. The major findings of this study are as follows: (1) HR is 
reduced by both S-VNS and P-VNS in a FREQ-dependent manner. However, the negative 
chronotropic effect of S-VNS at 10 Hz and 20 Hz is significantly smaller than that of P-
VNS and (2) S-VNS may acutely modulate the nonlinear relationship between short- and 
long-term HRV differently than P-VNS, as indicated by SD1/SD2 measurements. Overall, 
the results of our study suggest that acute S-VNS affects the dynamic changes in in-vivo 
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rat hearts, specifically HR and HRV in a different manner, when compared to traditional 
P-VNS. Hence, our study further supports the notion that different modes of stimulation 
provides different outcomes as measured by means of change in HR. We also highly 
suggest further investigations into characterizing the effects and elucidating the 
mechanisms of S-VNS as a novel neuromodulation technique under different diseased 
conditions. 
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CHAPTER 6 CONCLUSIONS 
AND FUTURE STUDIES  
 
This doctoral research applied principles of engineering and physiology as well 
fundamentals of cardiac electrophysiology to advance our understanding of vagus nerve 
stimulation (VNS) technology. This was accomplished by elucidating the mechanisms of 
action of VNS through 1) assessing atrial and ventricular electrophysiological properties 
after long-term VNS and 2) investigating the role of cardiac M2R-IKACh signaling pathways 
in mediating the chronotropic effects of acute VNS. In addition, this research also 3) led to 
the development and evaluation of a novel stimulation paradigm. 
6.1 Summary of Research Findings 
 
VNS has emerged as a promising therapy to treat cardiovascular diseases, which 
has been characterized by autonomic dysregulation or specifically overdrive of the 
sympathetic nervous system and withdrawal of the parasympathetic nervous system. Being 
known to provide parasympathetic innervation of many vital visceral organs including the 
heart, stimulating the vagus nerve may potentially be able to normalize parasympathetic 
activation of cardiac control reflexes. Despite showing promising results in both preclinical 
and clinical research, the mechanism of action of VNS remains unclear. This dissertation 
aims to improve our knowledge of VNS and to elucidate the mechanism of action in order 
to further optimize and improve VNS efficacy.  
First, it is without question that there are significant parasympathetic innervation in 
the atria (Coote, 2013; Hasan, 2013; Végh et al., 2016) and VNS has shown very promising 
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results to be able to treat heart failure (HF) and chronic myocardial-infarcted (MI) hearts 
(Beaumont et al., 2015; Kong et al., 2012a; Schwartz and De Ferrari, 2009; Uemura et al., 
2010b). Surprisingly in spite of this, the effects of both chronic MI and VNS on the 
electrophysiological properties of the atrium was unclear and inconsistent (Li et al., 2000; 
Sridhar et al., 2009; Yeh et al., 2008). As demonstrated in Chapter 2, this dissertation work 
found that chronic MI had pro-arrhythmic effects on the heart via shortening of the action 
potential duration (APD) and increased spatial APD heterogeneity (µ). Long-term VNS 
increased APD values and restored them back to the healthy animal values, thus 
demonstrating and confirming the therapy’s potential anti-arrhythmic and beneficial 
effects.  
There currently is a gap in knowledge in regards to how VNS may be able to 
modulate ventricular function and electrophysiology especially since it has been heavily 
reported that VNS exhibits ventricular anti-arrhythmic effects (De Ferrari et al., 2011; 
Schwartz and De Ferrari, 2009; Wu and Lu, 2011). Particularly, since physiology textbooks 
state that parasympathetic postganglionic supply is limited to only the atria, and none into 
the ventricles (and if there are any innervations, they are sparse and should not have any 
influence on ventricular function) (Coote, 2013; Jungen et al., 2017). However this 
supposition has since been challenged by several researchers using a variety of 
immunohistochemical, histological, western blot, and other methods to demonstrate that 
there are indeed rich parasympathetic innervations in the ventricles (Akiyama and 
Yamazaki, 2001; Coote, 2013; Jacobowitz et al., 1967; Kawada et al., 2001; Kent et al., 
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1974; Pauza et al., 2013; Pauziene et al., 2016; Taggart et al., 2011; Ulphani et al., 2010; 
Yasuhara et al., 2007; Zang et al., 2005; Zhan et al., 2013).  
With this challenged supposition and confirming the beneficial effects of chronic 
low-level VNS in the atrium of diseased hearts in Chapter 2, I then investigated the effects 
of chronic low-level VNS on ventricular function and electrophysiological properties in 
Chapter 3. Based on the physiology dogma that there is minimal parasympathetic 
innervation into the ventricles, I would expect that administration of VNS would induce 
very minimal changes to the ventricles, but this study showed otherwise. Using hearts of 
healthy rats, I confirmed positive anti-arrhythmic effects of VNS even in the absence of 
autonomic imbalance as none of the VNS-treated hearts and 75% of the non-treated hearts 
developed ventricular arrhythmias during our ex vivo programmed electrical stimulation. 
This study showed that VNS induced changes in ventricular electrophysiological changes 
that were able to render the hearts less vulnerable to inducible arrhythmias. At the same 
time, VNS also did not induce any detrimental effects on cardiac function as no significant 
changes to ventricular ejection fraction (EF) and APD heterogeneity index µ was observed.  
Now that my results from both Chapters 2 and 3 suggest that the parasympathetic 
branch may indeed affect atrial and ventricular functions through stimulation of the vagus 
nerve, I then used novel transgenic mice to specifically investigate the role of M2R-IKACh 
signaling pathway in mediating VNS effects. Chapter 4 describes the experiments that 
applied acute VNS in mice in which the cardiac IKACh channel was ablated constitutively 
or selectively in the atria or ventricles. This study was the first to provide distinctive 
evidence that M2R-IKACh signaling in the atria is required and plays the dominant role in 
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evoking the negative chronotropic and increased HRV effects of VNS. Our findings also 
further highlight the role atrial IKACh plays in arrhythmia inducibility and the potential of 
targeting this specific channel as a target for the management of atrial arrhythmias.  
The aim of the study detailed in Chapter 5 was to develop and test a new autonomic 
modulation stimulation protocol using stochastic stimulation (S-VNS) and compare it with 
traditional stimulation waveforms (P-VNS). Traditionally, the stimulation profile of VNS 
(P-VNS) consists of administering periodic, repetitive electrical pulses with the level of 
stimulation (i.e. intensity) determined by a selected frequency, pulse duration, pulse 
amplitude, and duty cycle which all can be adjusted via the radiofrequency communication 
link using a proprietary programming computer. The version of S-VNS developed and used 
in this study delivered electrical impulses to the nerve according to a Gaussian distribution 
of stimulation frequencies. The results suggest that acute S-VNS may indeed affect the 
dynamic changes in in vivo rat hearts, specifically HR and HR variability (HRV), in a 
different manner when compared to traditional P-VNS. This highlights the potential of S-
VNS being used in the clinical setting as S-VNS may enable some flexibility in nerve 
response by its ability to vary the stimulation intervals and providing a ‘pseudo-
intermittent’ stimulation. Specifically, even though the same mean FREQ in both P-VNS 
and S-VNS were delivered, S-VNS had a smaller drop in HR. This could make S-VNS 
suitable for treatment of diseased conditions in which a minimal change in HR is desired. 
Indeed, further investigations are absolutely necessary to characterize the effects and 
elucidate the mechanisms of S-VNS as a novel neuromodulation technique under different 
diseased conditions before being applied to humans.  
102 
 
Collectively, this work provides further evidence that the parasympathetic branch 
of the autonomic nervous system does indeed play a role in ventricular electrophysiology. 
Surprisingly, this work demonstrated that chronic VNS was able to prevent healthy hearts 
from having arrhythmias, even after applying a known arrhythmia-induced protocol. This 
anti-arrhythmic effect of VNS has always been reported in diseased hearts but not in 
healthy hearts where there is an absence of autonomic dysfunction. Hence, this dissertation 
suggests that VNS may not require sympathetic overdrive to induce its beneficial effects 
and is able to remodel the electrophysiological properties of the ventricles that makes the 
hearts less vulnerable to ventricular arrhythmias. Findings in this dissertation also 
contribute to current understanding of GIRK channel (specifically M2-IKACh) function in 
regards to VNS modulation in the heart. Furthermore, this work has set the stage for future 
studies to further investigate and analyze the role of the M2R-IKACh signaling pathway in 
the atria and the ventricles, each in isolation, in mediating the beneficial effects of chronic 
VNS.  
6.2 Future Work 
While the work presented in this dissertation improves on the current knowledge 
on the development and mechanisms of VNS for cardiovascular diseases, further 
investigative works needs to be done to obtain a more complete mechanistic understanding.   
6.2.1 Investigating VNS Effects on Calcium Dynamics 
Results from Chapter 3 suggest that chronic VNS is able to affect intracellular 
calcium dynamics as demonstrated in changes in the restitution properties at the APD50 
level. It has been previously reported that short-term VNS was beneficial to heart failure 
103 
 
(HF) rats through the improvement of excitation-contraction coupling by increased 
expression levels of ryanodine receptor 2 (RyR2) and sarcoplasmic reticulum Ca2+ ATPase 
(SERCA2) (Li et al., 2015; Zhang et al., 2015). Additional experiments will be needed to 
determine which myocyte membrane ion channels are indeed up- or downregulated by 
chronic VNS.  
Another approach to study how either acute or chronic VNS affects calcium 
dynamics is to use simultaneous optical mapping of voltage and intracellular Ca2+. 
Specifically, this method can be used to investigate both membrane voltage and 
intracellular Ca2+ simultaneously at each region of both VNS-treated and non-treated 
hearts, thereby allowing for the two parameters to be matched both spatially and 
temporally. Simultaneous optical mapping method has been previously developed and 
successfully implemented in Dr. Alena Talkachova’s laboratory (Visweswaran et al., 
2013). 
6.2.2 How Does VNS affect CV? 
Due to significant parasympathetic presence in the atria, it is well-accepted that 
VNS is able induce negative dromotropic effects in the atria. However, it remained unclear 
on how VNS may affect the conduction velocity (CV) in the ventricles. This dissertation 
suggests that chronic VNS is able to increase ventricular CV in the hearts of healthy rats. 
To investigate how VNS is able to modulate ventricular CV, I propose the following two 
investigative topics 1) gap junctions and 2) myocardial fiber orientation.  
Previous studies have shown that intercellular electrical uncoupling plays an 
important role in arrhythmogenesis during MI (Saffitz et al., 1999; Smith et al., 1995). 
Intercellular electrical coupling mainly occurs through gap junctions that are formed by 
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connexins, and one of the most important connexins in the heart is connexin-43 (Dhein et 
al., 2002). Connexin-43 (Cx-43) is the main electrical coupling protein in the ventricles 
and it is well-established that the amount and distribution of Cx-43 are significantly altered 
during ischemia (Gutstein et al., 2001; Jiang et al., 2008; Lerner et al., 2000; Papp et al., 
2007). It has been suggested that VNS is able to preserve Cx-43 in a MI rat model and 
improve ischemia-induced electrical instability (Ando et al., 2005; Wu and Lu, 2011). 
Nonetheless, this beneficial effect of Cx-43 preservation has only been shown in diseased 
hearts, but not in healthy hearts. I hypothesize that VNS may be able to increase ventricular 
CV by increasing the expression of Cx-43 and thus reduce the likelihood of ventricular 
arrhythmias, regardless of diseased or healthy hearts. Hence, I suggest future experiments 
to perform VNS in healthy animals, and then perform immunohistochemistry on sections 
of both VNS-treated and non-treated ventricular myocardium with anti-Cx-43 antibody to 
quantify level of Cx-43 expressions. 
The architecture of myocardial fibers is  known to play a role in electrical activation 
propagation (Kadish et al., 1988; Roberts et al., 1979). In fact, propagation is the fastest in 
the direction of myocardial fibers rather than across the fibers (Young and Panfilov, 2010). 
Therefore, another hypothesis I have to explain the increase in CV due to VNS is that 
chronic VNS is able to remodel the myocardial fibers in such a way that promotes smoother 
electrical propagation relative to non-treated VNS hearts. To investigate this hypothesis, I 
propose the use of optical methods such as optical coherence tomography (OCT) to acquire 
fiber orientation in heart tissues.  
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6.2.3 Identifying Peripheral Afferent and Efferent Neural Pathways 
Mediating the Therapeutic Effects of VNS 
This dissertation work has largely focused and assumed on the efferent 
parasympathetic control of the heart. However, afferent parasympathetic pathways may 
also play a role in the therapeutic effects by reflexively inhibiting sympathetic nerve 
activity to the heart and other organs.  
 
 
Figure 6.1: Schematic Illustration of Propose Methods to Study Afferent vs. Efferent 
VNS. Schematic illustration of the proposed (A) vagus nerve isolation (VNI) and (B) 
bilateral stellate ganglionectomy (SGX) procedures to investigating peripheral afferent and 
efferent neural pathways mediating the therapeutic effects of VNS. White and black arrows 
illustrate the directions of afferent and efferent nervous pathways, respectively.  
 
To test the hypothesis that the effects of VNS are mainly induced by vagal nerve 
afferent fibers rather than the direct stimulation of the heart through vagal efferent nerves, 
I propose to perform a vagus nerve isolation (VNI) surgical procedure. As shown in Fig. 
6.1(a), this surgical procedure involves isolating and transecting the vagal cardiac branch 
before it enters the heart to eliminate the contribution of efferent nerves to the effects of 
VNS. The vagal cardiac branch can be anatomically identified by its course from the 
thoracic vagus over the trachea toward the heart as described in (Rentero et al., 2002). The 
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VNI surgeries should be performed at the same time as the VNS stimulator implant 
procedure.  
To test the hypothesis that VNS may be mediated by activation of vagal afferents 
which can reflexively decrease cardiac sympathetic efferent activity, I propose to perform 
the bilateral stellate ganglionectomy (SGX) surgical procedure which ablates cardiac 
sympathetic nerves, as shown in Fig. 6.1(b) and described in (Xie et al., 2011). This 
proposed study will help lead to a better understanding of the role of cardiac sympathetic 
nerves in mediating the response to VNS. In other words, successful SGX procedures will 
block the delivery of neurotransmitters to the heart through sympathetic nerves; thus, the 
observed VNS effects will be solely due to the parasympathetic innervation through the 
direct vagus efferent nerve bundles. The SGX surgeries should be performed at the same 
time as the VNS stimulator implant procedure. 
6.2.4 Investigate S-VNS on Other Cardiac Responses and 
Miniaturization of VNS Pulse Generators 
As demonstrated in Chapter 5, acute S-VNS induced dynamical changes in in vivo 
rat hearts that is different from standard acute P-VNS. Specifically, S-VNS produced 
minimal changes in HR compared to P-VNS. Hence, I hypothesize that S-VNS may be a 
suitable treatment for other diseased conditions such as hypertension where a controlled 
drop in blood pressure within a minimal change in HR are desired. For the study described 
in Chapter 5, however, I only investigated the differences between P-VNS and S-VNS 
with respect to HR and HRV, and used a healthy rat model. Therefore, the next step is to 
apply S-VNS in diseased hearts and look into other cardiac responses. Specifically, I 
propose to further investigate the potential of S-VNS to treat hypertension using 
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hypertensive rats and investigate its effects on blood pressure. To do so, a hypertension rat 
model can be generated by feeding Dahl-salt sensitive rats with a high salt diet. Blood 
pressure can be acquired through a pressure catheter placed in the femoral artery while HR 
can be collected through external ECG electrodes. Systolic and diastolic blood pressure, 
pulse pressure, and blood pressure variability can then be calculated from the pressure 
waveform. Then after confirming that acute S-VNS is able to reduce blood pressure in 
hypertensive rats, chronic S-VNS can then be applied by collaborating with LivaNova to 
develop a fully functional, implantable, and chronic version of the S-VNS system. 
The VNS pulse generators that I used for this dissertation work typically have the 
following dimensions of 2.0 in x 2.0 in x 0.27 in and a weight of approximately 25 grams, 
as shown in Fig. 2-1. Therefore, putting in consideration the average weight of a healthy 
male wild-type C57BL/6J mouse is 27.7 grams at 12 weeks old (The Jackson Laboratory, 
2017), implanting our relatively huge stimulator on mice for chronic studies is extremely 
difficult and raises ethical concerns. Hence, I propose that future investigators develop 
miniaturized pulse generators that can be implanted into mice in order to perform chronic 
studies, especially on genetically engineered mouse models to further investigate several 
VNS mechanisms 
6.2.5 Determine the Optimal Time for the Onset of VNS 
However, even though this dissertation work and several other studies strongly 
suggest that VNS therapy is beneficial, it still remains unclear as to when be the optimal 
time to begin VNS therapy to the injured heart. Based on literature, previous studies show 
an inconsistency as to the onset of VNS therapy to treat ischemic heart diseases (Kong et 
al., 2012b; Shinlapawittayatorn et al., 2013; Uemura et al., 2010a; Zhao et al., 2013). While 
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some studies begin stimulation 5-30 minutes prior to the cardiac injury, there are also those 
that begin stimulation at the onset of ischemia or during reperfusion. Therefore, I highly 
suggest for future studies to determine the most optimal time for the onset of VNS in order 
to achieve the maximal therapeutic benefits, specifically anti-inflammatory and anti-
arrhythmic, to the injured heart. 
 
 
Figure 6.2: Assessment of MI size. Sections of the hearts were photographed to identify 
the ischemic area at risk (AAR, uncoupled by Evan’s blue dye), the MI size (unstained by 
TTC or the white region), and the non-ischemic zones (colored blue dye).  
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In fact, I have already begun these experiments and successfully established MI 
diseased rat models for Dr. Alena Talkachova’s laboratory to pursue this avenue of 
research. Specifically, I have established both myocardial ischemia/reperfusion (I/R) and 
chronic MI rat models. From my most recent experiments, I have used a 30 minute 
ischemia and 24 hour reperfusion rat model and applied intermittent VNS (~12% duty 
cycle) therapy. VNS therapy was provided to the rat 30 minutes prior to MI and rats 
continued to receive the therapy throughout the 24-hour reperfusion period. Afterwards, I 
sectioned the hearts in order to assess 1) myocardial injury via scar size (i.e., area at risk 
and necrotic area using Evan’s Blue Dye and Triphenyl tetrazolum chloride (TTC)), and 
2) inflammatory response in the myocardium by quantifying the number of macrophages 
(via immunohistochemistry of a macrophage and nucleus marker (i.e., CD68 and DAPI)). 
These preliminary results are summarized in Figs. 6.2 and 6.3. From these experiments, I 
have shown that VNS was able to reduce the MI size by quantifying the area at risk and 
necrotic area and then expressing as a percentage (Fig. 6.2, n = 2 (n = 1 for Sham and n = 
1 for VNS)). Note that I am unable to assess scar size and inflammatory response with the 
same hearts as the administration of Evan’s blue dye and TTC will affect and make 
immunohistochemical staining difficult. To quantify the number of macrophages (n = 6 (n 
= 3 for Sham and n = 3 for VNS)), I analyzed the immunohistochemical slides (60X 
magnification). Panel A of Fig. 6.3 shows sample immunohistochemical images of both 
Sham and VNS. Analysis was done using ImageJ and from each slide, counted the number 
of cells that express both CD68 and DAPI (i.e. excluding cells/area that either express only 
CD68). While the analysis suggest that our VNS therapy may not provide an anti-
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inflammatory effect (Fig. 6.3(b)), I still strongly hypothesize that VNS has anti-
inflammatory benefits but it will require some changes to the experimental protocol and 
further work to optimize the results. Suggested approaches include: 1) change the VNS 
therapy from intermittent to continuous stimulation and 2) in addition to macrophage 
counting, plan on performing cytokine analysis from blood draw and/or homogenization 
of myocardial tissue to gauge the inflammatory response. Results from this proposed study 
will be able to provide necessary information to guide therapeutic applications of VNS.  
 
Figure 6.3: Preliminary Assessment of Anti-inflammatory Effect of VNS. 30 minutes 
ischemia and 24 hours reperfusion was induced in rats (n = 6). VNS was provided 30 
minutes prior MI. A) Sample images of both Sham and VNS treated rats. B) Mean 
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quantification of macrophages. Red represents CD68, one possible marker for 
macrophages, and blue stains for DAPI. 
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